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ABSTRACT
In the presented work, we reviewed the protein glycation effect on
recombinant monoclonal antibodies (MAbs), and demonstrated an in vitro glycation
model on rhuMAb A was a successful tool to evaluate site-specific glycation. We also
implemented this model to study MAb glycation in three aspects: the formation of
glycation, the change of glycation adducts under thermal stress, and the control of
glycation adducts stability by formulation compositions.
A protein characterization study demonstrated that the in vitro forced
glycation model generated seven glycated amino acid sites on rhuMAb A. The lysine
residue K49 was the preferably site, while others sites were at various low levels of
glycation. Molecular dynamics (MD) analysis suggested that the high abundance of
lysine 49 glycation observed on rhMAb A may be assisted by a strong electrondonating environment created by three aspartates, with D30, D31, and D105 near
K49.
In the thermal stress stability study, the glycation adduct hydrolysis
reaction was more pronounced than the AGE formation. It was found that glycation
adducts hydrolysis continued for four weeks, but AGEs formation plateaued after
one week. The overall combination of both reactions caused a loss of glycation with
a first order reaction rate. The structure analysis of final degradation products agreed
with kinetic observation that reverse of glycation adducts was the main degradation
pathway of glycated rhuMAb A at 40°C in pH 6.5 phosphate formulation buffer.
Reverse of glycation adducts on K49 could be catalyst by its adjacent aspartic acids.

Influencing parameters of

glycation adduct degradation were also

evaluated. Three formulation composition factors: pH, buffer, and oxidation control
were compared. The study demonstrated the pH value was the key parameter that
controls degradation pathways. pH also determined the rate constant of hydrolysis of
glycated rhuMAb A. Buffer species and oxidation levels did not affect on the
glycation adduct stability under the studied conditions. In addition, the effect of
rhuMAb A’s initial glycation level was also evaluated. The study demonstrated that
higher protein glycation levels slow down the overall hydrolysis rate of glycation
adduct, presumably by providing a complex electron transferring system on protein.
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PREFACE
This thesis was composed in manuscript format for intended
publications. It contained four chapters: review of glycation on MAbs,
characterization of an in vitro force glycated model rhuMAb A, degradation of
glycated rhuMAb A, and the influceing parameter to control degradation of glycated
rhuMAb A. Except the chapter on review of glycation on MAbs, three other chapters
are intended for publication in journals.Therefore this thesis contained other
introductory remaks. Currently, these three chapters (manuscripts) are in preparation
stage prior to submission to journals.
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Chapter 1
Review of Formation and Characterization of Glycation on Therapeutic
Monoclonal Antibodies (MAbs)

Abstract
Recent studies have shown that protein glycation reactions can occur to
recombinant MAbs during cell culture in manufacturing, storage upon shelf life,
clinical administration and circulation in the human body. Difference in these process
conditions can generate structural heterogeneity in MAb glycation. Characterization
and control of glycation modification has become increasingly important to ensure
product quality as well as manufacturing process consistency for recombinant MAbs
in the biopharmaceutical industry. A series of analytical technologies has been
developed and applied to characterize the structure of glycated MAbs. These
technologies include: mass spectrometry, affinity chromatography, ion exchange
chromatography, biological binding activity, and others. Studies of certain MAbs have
shown that glycation may impair a MAb’s ability to bind antigens (Kennedy, D.M. et
al.1994), while, in contrast, studies of others MAbs demonstrated that glycation has
no effect in binding affinity (Quan, C. et al. 2008). Site specific glycation has also
been reported recently ( Zhang,B. et al. 2008, Gadgil, H.S. et al. 2010, Miller, A.K. et
al. 2011), which has enhanced research interest in the formation, degradation and
control of glycated MAbs. In the quality-by-design (QbD) paradigm for manufacturing
MAbs, the decision to monitor and control glycation for a given MAb would require a
thorough evaluation process, which is based on the impact of manufacturing
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parameters on MAb glycation modification and the effect of glycation on MAb’s
biological function with regards to both safety and efficacy (Quan, C. et al. 2008).
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Introduction
Glycation is a known reaction which occurs between reducing sugars and
amine groups on proteins, amino acids, and nucleotides. Intensive in vivo studies in
humans have shown that protein glycation is implicated in the pathogenesis of
multiple chronic diseases. The most common reducing sugar found in vivo is glucose,
which reacts with N-terminal amino acids or with free amino groups on lysine and
arginine residues. This initial reaction between glucose and amine group is often
referred as a glycation adduct. Further modification of glycation adducts result in a
variety of different products known as advanced glycation endproducts (AGEs)
(Maillard, L.C. 1912). This leads to irreversible modifications on the proteins (Sell, D.
R. and Monnier, V. M. 1989), which can subsequently cause tissue damage (Valcourt,
U. et al. 2007). Protein glycation level has been known as a biomarker for diseases.
For example, individuals with diabetes have higher serum glucose concentration, are
thought to be more prone to glycation than those in healthy persons. Therefore, the
extent of glycation of hemoglobin in vivo is a distinctive marker for diabetes
(Beisswenger, P.J. et al. 2001).
Glycation occurs in vitro as well. In the past several decades, an increasing
number of recombinant humanized monoclonal antibodies (MAbs) have been
developed as therapeutic agents (Figure1-1), due to their high specificity and affinity
to therapeutic antigen targets (Figure 1-2). As a manufactured therapeutic protein, a
MAb is subjected to many chemical modifications, including glycation throughout the
manufacturing process. Chemical modifications may result in structural changes,
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ultimately leading to potential biological function changes such as efficacy, safety and
clearance rate. Thus, understanding glycation formation, degradation and how to
control these processes on MAbs is important. The following sections summarize
reported studies about glycation modification on MAbs throughout their life cycle
including during cell culture, storage, administration in clinics and final circulation in
the body.
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Mechanism of Protein Glycation and Advanced Glycation Reactions
Glycation, originally described by Maillard (Maillard, L.C. 1912), refers to the
nonenzymatic reaction between reducing sugars and proteins. This process involves a
series of steps starting with the reaction between the reducing carbonyl group of a
carbohydrate and an amino group present on proteins, usually at the epsilon amine on
lysine residues or at the N-terminus, with initial formation of an aldimine (which is
known as a Schiff base) (Figure 1-3). This unstable aldimine linkage can then
rearrange to form a more stable ketoamine (which is known as an Amadori product)
(Bucola, R. and Cerami, A. 1992).
Although the ketoamine linkage is considerably more stable than the aldimine
linkage, it has been shown to be slowly broken under relatively mild conditions
(Acharya, A.S. and Sussman, L.G., 1984; Miller, A.K. et al. 2011). There are also
deglycating enzymes that limit glycation of intracellular proteins (Van Schaftingen, E.
et al. 2007). The nonenzymatic reverse hydrolysis reaction is straightforward,
releasing glucose and its C-2 epimer mannose, without much consequence (Zhang, Q.
et al. 2009). The enzymatic reverse reaction involves phosphorylation of the Amadori
product, followed by release of 3-deoxyglucosone.
Even though reverse of glycation reaction is relatively straightforward, the
forward reactions are more complex, generating a wide range of reactive carbonyl and
dicarbonyl compounds. These reactive intermediate carbonyl compounds may react
with proteins to form stable, irreversible adducts and cross-links, known as AGEs
(Figure 1-3). Oxidation and further rearrangement of the ketoamine and aldimine
products can also generate AGEs.
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Studies have shown that the extent of glycation of a protein depends on the
rate of formation of the Amadori product and the rate of reversal or conversion to
other products (Bucola, R. and Cerami, A. 1992; Cho, S.J. et al. 2007).
The study of AGEs is one of the most promising areas of research in chronic
inflammation diseases today. Although the Maillard reaction, AGEs formation, has
been known since 1912, it is only in the last 20 years that important works have done
to elaborate the mechanism of AGEs formation. In 1988, Namiki reported the
reactivity of different reducing sugars leading to AGEs formation. It was shown that
compared with glucoses, aldehydes with short carbon chains (2-3 carbons) react with a
model peptide, beta-alanine, faster and form AGEs more rapidly. Thus degradation of
glucose to smaller reducing sugar may accelerate AGEs formation (Table 1-1, Namiki,
M. 1988). In 2004, Jakus, et al. summarized three major pathways for AGEs
formation: the Wolf pathway for reducing sugar initiated AGEs; the Namiki pathway
for reverse aldose reaction of Schiff base to form AGEs; the Hodge pathway for
Amadori product dehydration, and oxidation formed AGEs. All three pathways are
thought to be trigged by oxidation (Jakus, V. et al. 2004).
Inhibitors, that prevent AGEs formation, have also been investigated by
researchers. An AGEs-inhibitor is a molecule that can interrupt the covalent
crosslinking of proteins and peptides by sugars or sugar derived oxidation products.
For example, it may contain a nucleophilic amino group that reacts carbonyl group on
reducing sugars to compete with epsilon amine groups on lysine residues and other
primary amines. Carnosine, a dipeptide, β-alanyl-L-histidine, found in long-lived
tissues, such as brain, at concentrations up to 20 mM in humans, has been regarded as
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an anti-oxidant and a free radical scavenger. More recently, an anti-glycating potential
has been discovered whereby carnosine can react with low-molecular-weight
compounds that bear carbonyl groups (aldehydes and ketones). Another example can
be found in the Wolf pathway. Since the crucial step of AGEs crosslinking depends
on the presence of transition metals for the formation of glycoxidation products and
radicals, a family of metal chelators and radical scavengers (especially superoxide
dismutase mimetics) could be regarded as AGEs-inhibitors. In addition, several
natural and synthetic compounds (Figure 1-4) have been shown to be inhibitors of
AGEs-formation in vitro and in vivo (Cameron, N.E. and Cotter, M.A. 1993).
In short, the chemical processes and pathways that ultimately lead to AGEs
formation step by step have yet to be fully clarified. As our knowledge of AGEs
expands, it is becoming apparent there are many unknown AGEs, while those that
have been characterized are both complex and heterogeneous, making it an important
area of research.
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Glycation and AGEs in Aging and Diseases
There is an increasing amount of evidence that AGEs may play a role in
Alzheimer's disease (AD), diabetes and aging, as well as other chronic disease
complications. The presence of AGEs are closely related to hyperglycaemia and the
patho-biochemistry of AGEs could explain many of the observed changes in diabetes
related complications.
From biochemical, cell based, and animal studies, it has been demonstrated
that AGEs accumulate as a function of the level of chronic hyperglycemia. It is
thought that AGEs accumulation in vivo causes dysfunctional changes in extracellular
matrix, abnormal receptor-mediated production of cytokines, and altered function of
intracellular proteins.
In the early 80's, Monnier and Cerami (Monnier, V. and Cerami, A. 1981),
the pioneers of the nonenzymatic glycation theory of aging, proposed that the AGEsmediated crosslinking of long-lived proteins contributes to the AGEs-related decline
in the function of cells and tissues in normal aging (Table 1-2) (Brownlee, M. et al.
1992). Recent progress in the study of chronic diseases has confirmed that AGEs play
a significant role in the evolution of vascular complications in aging, diabetes and
renal failure. Pathological results showed that chronic inflammation may be triggered
by endogenous trans-membrane receptor of AGEs ( RAGEs) ( Basta, G. et al. 2002).
Among the many factors proposed to be involved in the etiology or
progression of AD, AGEs are a relatively new and interesting approach to unravel the
mysteries of the etio-pathogenesis of this multi-factorial disease. Recent studies
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suggest that AGEs are active promoters of the progression of AD, not only simply a
secondary epiphenomenon (Shaw, S.M. and Crabbe, M.J. 1994). However, one has to
be careful not to overestimate AGEs’ role in the disease process as long as only
circumstantial evidence is presented. Therefore, the specific role of AGEs and which
particular AGEs are involved in the disease complications needs to be established. The
possibility of effective therapeutic intervention enhances the importance of detecting
AGEs. Advancements in measuring extent and type of AGEs using reliable methods
will help to determine the role that AGEs have in the pathogenesis of many diseases.
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Overview of Chemistry, Manufacture and Controls of Therapeutic Monoclonal
Antibodies (MAbs)
Therapeutic MAbs, like other therapeutic proteins, are enormously complex
drugs. They are typically produced in mammalian tissue culture cells through recombinant DNA technology (Goetze, A.M. et al. 2010). MAbs are a fast growing
therapeutic modality in the pharmaceutical industry due to their higher specificity,
lower toxicity, and greater in vivo predictability than small molecule pharmaceuticals
(Banks, D.D. et al. 2009). However, unlike small molecule drugs, protein drugs are
generally more susceptible to various conformational instabilities which can
potentially influence immunogenicity and biological activity (Banks, D.D. et al. 2009).
As of May 2008, there were 15 recombinant MAbs and fusion proteins
approved in the US for human therapeutic use (Table 1-3), with the majority approval
for oncology and immunological indications (Zider, A. and Drakeman, D.L. 2010). To
date, There are over 450 MAb products that are under development across the
biopharmaceutical industry.
The manufacturing processes for recombinant MAb drug substance (DS) and
drug product (DP) are complex. A stable chinese hamster ovarian (CHO) cell line
contains recombinant DNA capable of expressing a desired MAb product. Cells are
cultured and aliquots of cell are frozen in small vials. When production occurs,
thawed cell line vials are cultured through a series of reactors at different scales
(milliliter to kiloliter). Eventually, cells are grown in a production bioreactor using
serum-free modified medium supplemented with glucose and, as appropriate,
galactose. Cells are separated from the cell culture fluid using centrifugation followed
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by filtration. The harvested cell culture fluid is purified across multiple column
chromatography steps, typically in series which may include for example: a protein A
affinity column, an ion exchange column, and a hydrophobic interaction column and/
or one more additional ion exchange column or other chromatography column(s).
Virus inactivation and filtration operations are also designed and executed during the
downstream processing. The purified MAb product is eventually formulated and filled
into either drug product vials or pre-filled syringes. Subsequently, the DP is stored
under recommended storage conditions before being shipped for clinical use.
Health authority approval for these protein drugs requires chemical and
biological analyses designed to determine product identity, purity, and potency—
which is not a trivial task for an approximately 1,300-amino-acid, 150-kDa heterodimer structure. The resulting analytical description encompasses the protein sequence,
size, and charge as well as the degree of heterogeneity associated with each parameter.
To complete the physiochemical and biological characterization, forms of variants
need to be identified and their impact on potency needs to be determined. Typical
recombinant protein modifications include asparagine deamidation, aspartate
isomerization, methionine oxidation, protein aggregation and fragmentation, and
protein glycation.
Control of micro-heterogeneity within defined analytical specifications has
been used in quality control laboratories to guarantee consistent product quality during
current good manufacturing process (cGMP) (Goetze, A.M. et al. 2010). Defining and
adhering to the appropriate range of specifications ensures drug safety and efficacy to
patients.
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Formation of Glycation Products During Cell Culture Step in Manufacturing of
Therapeutic Monoclonal Antibodies
Recombinantly produced MAbs are exposed to reducing sugars during
mammalian cell culture after they are secreted into the cell culture medium that
contains sugars. Sugars are present in medium as energy and carbon sources for the
cells, and as a way to modulate glycosylation. For example, galactose may be added to
the cell culture medium to control the level of galactosylation (Clark, K.J. et al. 2005).
In addition, standard process parameters of cell culture such as temperature (~37°C
physiological condition), pH (~ pH 7.4 physiological conditions), time (10-14 days),
and reactant (amine and sugar) concentrations, affect both the glycation reaction
kinetics and extent.
Under typical batch-feed manufacturing conditions for MAbs, the cell culture
medium is maintained at approximately 10,000-fold molar excess reducing sugar per
mole protein product for the cell culture duration, indicating that the bimolecular
glycation reaction kinetics would be pseudo first-order for the protein (Quan, C . et al.
2008). However, each MAb molecule has more than 100 primary amines, and the cell
culture medium also contains significant levels of free amino acids and other
compounds containing potentially reactive amines, thereby reducing the sugar molar
excess for the glycation reaction. The protein glycation reaction extent is thought be
governed mostly by the reactivity of accessible amino groups, although different
sugars have different reactivity. For example, galactose is 5-fold more reactive than
glucose (Bunn, H.F. and Higgins, P.J. 1981). In the artificial environment with
complex chemical components present in cell culture medium and feeding conditions,
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protein glycation occurrence can be expected, but the reaction kinetics and extent can
be difficult to predict and control.
As the protein sequence differs between MAb molecules, the degree of
glycation would also be expected to differ, even under similar cell culture conditions.
Differences in cell culture process length, expressed MAb concentration, glucose feed
strategy and the glucose concentration in the medium feeds would also be expected to
impact glycation levels, making this a difficult problem to understand and control
(Zhang, B. et al. 2008, Miller, A.K. et al. 2011, Yuk., I.H. et al. 2011).
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Specificity and Structural Analysis of Glycation Sites on MAbs

In the past several decades, the primary sites of glycation have been analyzed
for a number of proteins under a variety of conditions. On some proteins, glycation is
evenly distributed, while on other proteins, the N-terminus (Holmquist, W.R. and
Schroeder, W.A. 1964) and specific lysine residues (Zhang, B. et al. 2008, Gadgil,
H.S. et al. 2010, Miller, A.K. et al. 2011) can have a greater degree of modification.
Glycation distribution difference between studied protein molecules indicates that
sequence or structure may determine the specificity of glycation reactions. In the past,
it was thought that the apparent pKa and exposure of the amine attachment site
determines the degree of Schiff base formation. In addition, the proximity of amino
acids capable of proton abstraction helps catalyze the formation of the ketoamine, or
Amadori product (Venkatraman, J. et al. 2001, Zhang, B. et al. 2008). Buffer
components that can bind near the reaction site and abstract protons from sugars, such
as phosphate, can also serve as a catalyst to increase the rate of formation of stable
products (Watkins, N.G. et al. 1987). Thus, the protein amino acid sequence and
reaction conditions can all affect the site specificity of glycation reactions.
A MAb contains many primary amine groups. In addition to four N-terminal
amino acids, most MAbs have approximately 80 Lys residues, giving MAbs many
potential sites for glycation (Lapolla, A. et al. 2000).
Historical data has shown that a typical MAb can be modified by glucose
that results in very low abundances of glycation, with sites distributed over different
amino acid residues. Often, the abundance of glycation product can be below the
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detection limit of many analytical methods. For example, a study by Quan and
coworkers showed that MAbs produced in a 10 day glucose containing cell culture
were approximately 18% glycated overall including both light chains, and both heavy
chains. The quantification of this MAb’s overall glycation is based on percentage of
glycated MAb separated from total MAb by boronate affinity chromatography (Quan,
C. et al. 2008). Within this 18 % population of glycated MAbs, the glycation
modification appeared as mono-glycation on 8 lysine residues on half of the molecule
with low frequency (1–12%) at each of the eight lysine residues. (Quan, C. et al. 2008).
These glycated species were separated from nonglycated material based on an
approximately 0.05-pI charge unit difference and appeared as an acidic variant form in
charge-based assays (Quan, C. et al. 2008). Because of the disperse locations and low
abundance of glycation, chromatography methods did not produce good charge- or
hydrophobicity-based separation to detect glycation modifications, therefore different
glycation modification could not be detected.

However, mass spectrometry and

boronate affinity chromatography can be used to detect glycation. Both methods
coalesce multiple glycation adducts into a single-unit modification, allowing
separation between glycated and unglycated protein species, and specific detection on
large and complex molecules such as MAbs (Zhang, B. et al. 2008, Quan, C. et al.
2008).
In recent years, researchers have reported site specific glycation on MAbs
(Miller, A.K. et al. 2011, Gadgil, H.S. et al. 2010, Zhang, B. et al. 2008). For
example, Zhang’s group published a significant amount of work of a site specific
glycation on lysine K49 of a particular MAb molecule. The glycation level on this
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particular lysine K49 residue can be as high as 50% under typical cell culture
conditions. Intensive studies have been carried out to study the effect of glucose to
protein ratio and glucose feed strategies on MAb glycation in the hope of optimizing
the cell culture condition to control the total glycation level of the MAb (Yuk, I.H. et
al. 2011). This finding contrasts with historical data that have suggested that glycation
sites are typically located randomly at all accessible lysine residues distributed over
the entire molecule (Zhang, B. et al. 2008).
To date, only a few publications had proposed a mechanism of site specific
glycation on MAbs. One theory is that site specific glyaiton is due to proton transfer
with assistance from nearby amino acids. Sometimes,a histidine residue is
hypothetically involved ( Quan, C. et al. 2008). In other cases, a aspartic acid residue
is thought to be involved (Zhang, B. et al. 2008). However, the exact mechanism of
site specific glycation on MAbs is till yet to be determined. This uncertainty enhances
the interest of study in the formation and control of glycation in MAbs.
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Glycation in MAbs Drug Product Stability and Administration
Protein glycations may occur during formulation, packaging, long term storage,
or clinical administration steps, where sugars are commonly used as excipients in
liquid or lyophilized formulations of therapeutic proteins (Chang, B.S. and
Hershenson, S. 2002). This modification of glycation is one of the primary reasons
that formulation scientists tend to avoid using reducing sugars (glucose, lactose,
fructose, maltose) in formulations.
Even for non-reducing disaccharides, such as sucrose, there is still a potential
to generate reducing sugars by in situ hydrolysis, resulted in subsequent glycation
modification. For example, sucrose can undergo hydrolysis – e.g. at low pH – to
glucose and fructose. Smales, et al. demonstrated this hydrolysis for sucrose-based
formulations undergoing viral inactivation at elevated temperatures (Smales, C.M. et
al. 2000 and 2001). Similarly, glycation in sucrose-based formulations has been
observed during storage studies (Fischer, S. et al. 2008, Gadgil, H.S. et al. 2007),
although, at elevated temperatures and acidic pH. These extreme conditions are not
within typical pharmaceutical formulation conditions, therefore the risk of protein
glycation induced by sucrose hydrolysis in protein therapeutic is very low during the
storage shelf life.
Finally, for delivering a drug to patients, sugars are often used in IV
(intravenous) solutions to prevent precipitation of proteins, attain isotonicity of drug
and provide an energy source for patients. Since some of the sugars commonly used
for these purposes are reducing sugars (5% dextrose), the spontaneous glycation of
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MAbs during IV administration cannot be prevented. In a recent study, two MAbs
were 70% glycated after a 14 day incubation with 5% dextrose at ambient temperature.
(Fischer, S. et al. 2008). However, under typical clinical conditions, MAbs are only in
contact with IV solutions for a maximum of 8 hours. To the best of our knowledge,
the glycation of MAbs under administration conditions in a clinical setting has not yet
been reported yet (Vrdoljak, A. et al. 2004).

Nevertheless, it is important to

understand the glycation effect on MAbs during IV delivery, as drug compatibility
with administration route is the final controllable step for ensuring the MAb’s safety
and efficacy to patient.
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Impact of MAb Glycation on Its Biological Activities
Glycation of MAbs is of special interest due to the possible influence on the
functionality of antigen binding, Fc effector function, and neonatal Fc receptor
(FcRN) binding.
Antigen Binding
Quan, et al. 2008, studied the effect of glycation on in vitro potency of a MAb,
where the second most susceptible site to glycation was located within the second
complementarity-determining region (CDR) on the heavy chain (HC CDR2 K65). The
glycated and unglycated MAb were separated by and fraction collected from boronate
affinity chromatography. In vitro biological activity were assayed for each fraction.
Even though there was glycation at an active binding site, there was little observable
effect on bioactivity for the glycated boronate fraction, compared to unglycated. The
glycated MAb showed similar binding activity to a biologically functional ligand.
Although glycation at the 10% level at this one residue (K65) within one CDR was
insufficient to affect potency, additional increase in glycation levels may ultimately be
expected to interfere with the ligand-binding ability of the MAb. Also, the effect of
glycation modification impact depends on the location of modified lysine, e.g. whether
it is directly involved in antigen binding (Quan, C. et al. 2008).
Researchers are also interested in glycation impact on the stability of antibodyantigen complex. For example, Kennedy and coworkers reported antibody-antigen
complex study based on surface plasmon resonance, in 1994. Although glycated
MAbs had similar association constant (kass) with their antigen, compared with
unglycated MAbs, the glycated MAbs have significantly higher dissociation constant
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(kdis) with their antigen, indicating that the glycated MAbs dissociate with their
antigen faster. Therefore, glycation lowered the affinity ( Kd= kdis/kass) of MAbs to
their antigens ( Kennedy, D.M. et al. 1994). Because of the different approaches and
detection techniques used, the results from different studies were not coherent,
especially regarding the influence of glycation on the ability of MAbs to bind antigens
and induce the complement cascade.

Fc effector Function, and FcRN Binding
Forced glycation studies using high pH conditions have shown that Fc
functions of human antibodies, such as protein A binding and complement activation,
can be impaired by glycation (Dolhofer-Bliesener, R. and Gerbitz, K.D. 1990).
However, under physiologic conditions, binding activity of the Fc is less sensitive,
presumably due to lower levels of glycation.
Goetze, et al. 2012 reported glycation of MAbs can result from incubation with
a reducing sugar during circulation in vivo. The contributions to total glycation from
the labile aldimine and more stable ketoamine forms were separately monitored via
the use of selective sodium borohydride reduction. Since the Fab protein sequences are
versatile, the Fab susceptibility to glycation, differs between antibodies. A number of
studies have focused primarily on the conserved Fc regions (Goetze, A.M. et al. 2012).
An attempt was made to model physiological glycation rates observed using a simple
in vitro system. The impact of Fc glycation on function was also explored using
surrogate binding assays that probed the interaction between MAbs and FcγRIIIa,
neonatal Fc receptor (FcRn) and immobilized protein A (Goetze, A.M. et al. 2012).
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Upon injection of a recombinantly produced human therapeutic IgG into
humans, changes in the glycation levels could be observed as a function of circulation
time (Goetze, A.M. et al. 2012). Mass changes on the individual MAb polypeptide
chains as the results of glycation were determined using reversed-phase liquid
chromatography/mass spectrometry. Changes to the light and heavy chains were low
but easily detectable at 0.00092 and 0.0021 glucose additions per chain per day,
respectively. Levels of glycation found on the Fc portion of MAb were, on average,
0.045 glucose molecules per fragment, after being isolated from healthy subjects. In
vivo glycation rates can be approximated in vitro by modeling the physiological
glycation reaction with a simplified incubation containing physiological glucose
concentrations, pH and temperature, but with a high concentration of a single purified
MAb. To test the impact of glycation on MAb function, highly glycated IgG1 and
IgG2 were prepared containing on average 42–49 glucose molecules per MAb. In this
study, binding to FcγIIIa receptors, neonatal Fc receptor, or protein A was similar or
identical to the non-glycated MAb controls. Although the modifications were well
distributed throughout the protein sequence, and at high enough levels to affect the
elution position by size-exclusion chromatography, no changes in the tested Fc
functions were observed (Goetze, A.M. et al. 2012).
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Conclusions
Protein glycation reactions can occur to recombinant MAbs during many
manufacturing process steps such as cell culture and storage, as well as during clinical
administration to a patient and circulation in human body. Cell culture process is the
initial place generating glycated recombinant MAbs. Clinical administration is the
final step for controlling MAb glycation before introduction into patients.
Glycation modification results in structural heterogeneity in the MAbs. It
changes MAbs charge, target binding capacities, and degradation rates (Zhang, Q. et
al. 2009). However, the site specific glycation mechanism and effect of glycation
impact on efficacy, safety and stability of MAbs are not well understood.
Development of sensitive and specific methods to monitor advanced glycation
products is important to fully understand and monitor glycation during the
manufacturing process and clinical administration of MAbs. Improved and more
specific assays are also needed to assess the impact of novel protection strategies
aimed at designing glycation inhibitors for therapeutic applications (Zhang, Q. et al.
2009).
In the quality-by-design (QbD) paradigm for manufacturing MAbs, the
decision to monitor and control glycation for a given MAb would be a thorough
evaluation process based on the impact of manufacturing parameters on MAb

22

glycation modification and the effect of glycation on MAb’s biological function for
safety and efficacy (Quan, C. et al. 2008).
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Figure 1-1: History of therapeutic monoclonal antibody from concept to FDA
approval.
Reference: Weiner, L.M., Surana, R. and Wang, S. 2010.
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Figure 1-2: Diagram of structure of an antibody and its bioactivity.
Reference: Weiner, L.M., Surana, R. and Wang, S. 2010.
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Figure 1-3: Chemistry of glycation reaction and advanced glycation reaction.
Reference: Munch, G., Thome, J., Foley, P., Schinezel, R., Riederer, P. 1997.
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Figure 1-4: Chemical structures of the AGE-inhibitors: aminoguanidine, carnosine and
tenilsetam.
Reference: Cameron, N.E. and Cotter, M.A. 1993.
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Sugar
Glucose (C-6)
Fructose (C-6)
Xylose (C-5)
Methylglyoxal
(C-3)
Glyceraldehyde
(C-3)
Glycolaldehyde
(C-2)

Formation of
Chromophores (Browning)
1
0.74
8.74
654

Radical Formation
(Intensity of ESR Spectra)
++
+
++
Not Determined

1976

+++

2109

++++

Table 1-1: Reactivity of different sugars (with beta-alanine as amino component) in
the Maillard reaction.
Reference: Namiki, M. 1988.
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Failure of Maintenance in Cells or Tissues
Neurones
Retina, Lens
Insulin Metabolism, Signaling
Blood Vessels
Glomeruli

Major Pathologies
Dementias
Blindness
Complications of diabetes
Cardiovascular Diseases
Renal Failure

Table 1-2: Human degenerative diseases with a proposed involvement of AGEs.
Reference: Brownlee, M., 1992.
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Trade and nonproprietary names

Type

Indication

Amevive (alefacept)

Fusion

Immunology

Avastin (bevacizumab)

Naked

Oncology

Bexxar (tositumomab)

Conjugate

Oncology

Campath (alemtuzumab)

Naked

Oncology

Cimzia (certolizumab pegol)

Fragment

Immunology

Enbrel (etanercept)

Fusion

Immunology

Erbitux (cetuximab)

Naked

Oncology

Herceptin (trastuzumab)

Naked

Oncology

Humira (adalimumab)

Naked

Immunology

Lucentis (ranibizumab)

Fragment

Ophthalmology

Mylotarg (gemtuzumabozogamicin)

Conjugate

Oncology

Orencia (abatacept)

Fusion

Immunology

Orthoclone OKT-3

Naked

Immunology

Raptiva (efalizumab)

Naked

Immunology

Remicade (infliximab)

Naked

Immunology

ReoPro (abciximab)

Fragment

Cardiovascular

Rituxan (rituximab)

Naked

Oncology

Simulect (basiliximab)

Naked

Immunology

Soliris (eculizumab)

Naked

Immunology

Synagis (palivizumab)

Naked

Infectious Disease

Tysabri (natalizumab)

Naked

Immunology

Vectibix (panitumumab)

Naked

Oncology

Xolair (omalizumab)

Naked

Immunology

Zenapax (daclizumab)

Naked

Immunology

Zevalin (ibritumomab
tiuxetan)

Conjugate

Oncology

Table 1-3: Monoclonal antibodies and fusion proteins approved in the US as of May
2008.
Reference: Zider, A. and Drakeman, D.L. 2010.
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Abstract
Recently, a site specific glycation on lysine K49 of rhuMAb A was reported
(Zhang, B. et al. 2008), with a proposed mechanism of spatial proximity effect
between lysine residue (K49) and nearby aspartate (D31) residue. To elucidate the
mechanism of site specific glycation on K49 of rhuMAb A, an in vitro forced
glycation model was employed to generate fully glycated rhuMAb A, a detailed
analytical characterization on the glycated rhuMAb A was performed. Finally,
molecular dynamics simulations were used to model the local electrostatic
environment under solution conditions.
The in vitro forced glycation model showed that seven glycation sites
were identified on this rhuMAb A, by using a series of analytical technologies such
as boronate affinity chromatography, ESI-Mass spectrometry and peptide map.
Among these seven sites, K49 was the primary glycation amino acid residue with
90% glycated. The six other sites were at various low levels of glycation. Molecular
dynamics (MD) analysis results provided an insight that the high abundance of K49
glycation observed on rhMAb A may be caused by a strong electron-donating
environment with three surrounding aspartates: D30, D31, and D105.
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I. Introduction
In the past decades, there has been an increasing number of recombinant
humanized monoclonal antibodies (MAbs) developed as therapeutics due to their
high specificity and affinity to therapeutic antigen targets. As manufactured proteins,
MAbs have the potential to be chemically modified during manufacturing process.
MAbs are typically manufactured via a 10-14 day cell culture process. In this process
a MAb is produced in Chinese Hamster Ovarian cells (CHO) then secreted outside
the cell, into the culture medium, which contains glucoses as the cell’s nutritional
carbon source. This protein-glucose contact results in MAbs glycation (Quan, C. et
al. 2008, Zhang, B. et al. 2008).
In most MAbs, the glycation level is <15% and widely distributed over the
entire MAb molecule. In recent years, researchers have also reported site specific
glycation on MAbs (Miller, A.K. et al. 2011, Gadgil, H.S. et al. 2010, Zhang, B. et
al. 2008). Zhang’s group, in particular, has published a significant amount of work
describing a site specific glycation on lysine K49 of a rhuMAb A molecule. The
glycation level on this particular lysine K49 residue can be as high as 50% under
typical cell culture conditions. Intensive studies have been carried out to study how
glucose to protein ratio, and glucose feed strategies can be altered to optimize the
cell culture condition. The ultimate goal is control the total glycation level of
rhuMAb A (Yuk, I.H. et al. 2011).
In the artificial environment with complex chemical components present in
cell culture media and feeding conditions, the glycation kinetics and extent on MAbs
can vary with cell culture conditions (Zhang, B. et al. 2008; Yuk, I.H. et al. 2011).
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As the protein sequence differs between MAb molecules, the degree of glycation
would also be different, even under similar conditions. The uncertainty of controlling
MAbs glycation enhances the interest of study in the mechanism site-specific of
glycation in MAbs.
To date, only a few publications have proposed a mechanism of site-specific
glycation on MAbs. The proposed glycation mechanism suggests that nearby amino
acids may facilitate proton transfer. Sometimes, a histidine residue is thought to be
involved (Quan, C. et al. 2008), in other cases an aspartate residue may be involved
(Zhang, B. et al. 2008).
With a great amount of mutation work on rhuMAb A, Zhang proposed that
an adjacent aspartate residue D31 is the local catalyst for site specific glycation in
rhuMAb A. D31 is spatially located 11 Å to lysine residue K49 based on the crystal
structure of rhuMAb A. The mutation of this D31 to other amino acids may reduced
the glycation level of K49. However, in Zhang’s study, there were several cases
where K49 lysine was still glycated up to 20% after replacing D31 with different
amino acids.
In order to further examine the mechanism of site specific glycaiton on K49
of this rhuMAb A, we employed an in vitro forced glycation model to generate close
to 100% glycated rhuMAb A. We also performed comprehensive analytical
characterization on the glycated rhuMAb A produced using this model system. Then,
we applied molecular dynamics simulations to determine the local environment of
the primary modified lysine K49 by mimicking the rhuMAb A in aqueous solution.
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II. Experimental
II. 1. Materials and Reagents
A regular lot of rhuMAb A (27 mg/mL, PBS buffer, pH 7.4) bulk material
was obtained from Genentech. Sequencing grade trypsin (TPCK treated) was
purchased from Promega (Madison, WI), and Peptide: N-glycosidase F (PNGase F)
from New England BioLabs Inc (Ipswich, MA). N-(2-Hydroxyethyl)piperazine-N¢(3-propanesulfonic acid) (EPPS; 99.0%) and dithiothreitol (DTT; ultrapure) were
obtained from USB Corp. (Cleveland, OH). D-Sorbitol (minimum 98%), R-Dglucose

(ACS

reagent),

iodoacetic

acid

(IAA;

_99%),

and

R-cyano-4-

hydroxycinnamic acid (CHCA) were procured from Sigma-Aldrich (St. Louis MO).
HPLC grade acetonitrile (ACN) and methanol were purchased from Fisher Scientific
(Fair Lawn, NJ). Water used in all experiments was obtained from a Milli-Q Plus
purification system (Millipore, Bedford, MA).
II.2. In Vitro Glycation of rhuMAb A
The rhuMAb A in PBS buffer, pH 7.4, was further glycated in vitro. rhuMAb
A was buffer exchanged into glycation buffer with dialysis prepared in 15 ml
cassette with 10kD membrane. The final in vitro glycation solution contains
50mg/ml rhuMAb A with 1200 mM D-glucose, in 20 mM sodium phosphate buffer,
pH 7.4. The in vitro glycation solution was kept in an incubator at 37 °C for 24 hours.
The in vitro glycation solution was immediately buffer exchanged using a 15 ml
dialysis cassette with 10kD membrane into phosphate buffer, pH 6.5. The samples
were then stored at -70°C until analysis.
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II.3. Boronate Affinity HPLC
Early stage glycation adducts often can be identified by a boronate affinity
HPLC method to determine the overall glycation level on a whole protein, using a
TSK gel boronate 5PW column 7.5x75mm. The mobile phase A was 50mM EPPS,
10mM Tris, 200mM NaCl, at pH 8.7, and mobile phase B, 500mM sorbitol added
mobile phase A. The mobile phase flow rate 1 mL/min and the column temperature
was maintained at 40°C with a UV and fluorescence detector. The gradient for
HPLC elution required optimization for rhuMAb A. (Zhang, B. et al. 2008)

II. 4 Enzymatic Digestion of rhuMAb A
Several enzymatic treatments were performed on rhuMAb A samples before
they were analyzed for reverse phase-HPLC, or mass spectrometric analyses, to
determine the amino acid sequence and structural integrity of rhuMAb A.
PNGase F Treatment. PNGase F was used to remove the oligosaccharides in
the Fc portion of a MAb. The rhuMAb A samples were buffer exchanged into 50
mM Tris buffer, pH 7.5, using a NAP-5 column. The protein concentration was
adjusted to 2.5 mg/mL. PNGase F was added in an enzyme-to-substrate ratio of
1:600 (w/w). The digestion was performed at 37°C overnight (15 h).
Tryptic Digestion. Prior to tryptic digestion, rhuMAb was reduced with DTT
and then alkylated with IAA. Typically, 250 µL of antibody sample (2 mg/mL) was
mixed with 20 µL of 1 M DTT in 730 µL of 6 M guanidine, 50 mM Tris, pH 8.0.
The mixture was incubated at 37 °C for 1 h. It was then cooled to room temperature,
and 50 uL of 1 M (IAA) in 1 M NaOH was added for carboxymethylation. The

36

alkylation reaction was incubated at room temperature in the dark for 15-20 min. The
residual IAA was quenched by the addition of 10 µL of 1 M DTT. The reduced and
carboxymethylated rhuMAb A was then buffer exchanged into the digestion buffer,
which contained 25 mM Tris, 1 mM CaCl2, pH 8.3, using a PD-10 column
(Sephadex G-25 medium, GE Healthcare). Trypsin was added at an enzyme-tosubstrate ratio of 1:50 (w/w). The solution was mixed briefly and incubated in a
37°C water bath for 5 h. The digestion was terminated by adding 0.3% (v/v)
trifluoroacetic acid (TFA) to the solution. The digest was then stored at -70°C until
analysis.

II.5. Reverse Phase-HPLC with Electron Spray Ionization/ Mass Spectroscopy
(RP-HPLC-ESI/MS)
The molecular masses of the intact, PNGase F-treated, and reduced rhuMAb
A samples were determined by using a LC/ESI-MS setup coupled with an Agilent
1090 HPLC system with a PE Sciex API 3000 electrospray ionization triplequadrupole mass spectrometer (Applied Biosystems, Foster City, CA). The samples
were desalted by reverse phase –HPLC (RP-HPLC) using a capillary column (Poros
R1, 0.33 _ 200 mm) equilibrated at a flow rate of 200 uL/min with 0.2% formic acid
(solvent A) at a column temperature of 40 °C. Samples were eluted using a linear
gradient from 25% solvent B (0.2% formic acid in acetonitrile) to 70% solvent B
over 16 min. The elutant from the RP-HPLC column was directed into the mass
spectrometer operating in the positive ion mode. For post-reduction analysis,
samples were incubated in 25 mM DTT for 15 min at 37 °C prior to LC/MS analysis.
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II.6. Tryptic Peptide Mapping
The flow through factions (intact unglycated rhuMAb A) and retained factions
(intact glycated rhuMAb A) on BAC were collected. Both glycated and unglycated
rhuMAb A fractions were then digested by enzyme trypsin. Peptides profiles of
tryptic-digested rhuMAb A were analyzed subsequently by an RP-HPLC using a
Jupitor C18 2.0x250 mm column at 45°C and UV detection at 214nm. The flow rate
was at 0.25ml/min, in mobile phase A: 0.1% TFA in water and B: 0.09% TFA in
acetonitrile. The gradient was optimized for this rhuMAb A. By comparing the
peptide maps of glycated and unglycated rhuMAb A, the distinctive peptide factions
on glycated rhuMAb A were collected for further characterization by MALDI-TOF
MS/MS sequencing.

II.7. Protein Chip Matrix Assisted Laser Desorption Ionization- Time-Of-Flight
mass spectrometry (MALDI-TOF)
Isolated tryptic peptides were spotted individually on a SCOUT 384 multiprobe plate with a CHCA matrix and analyzed in the positive mode using a Bruker
Ultraflex-I MALDI-TOF-TOF mass spectrometer (Bremen/Leipzig, Germany).
Selected precursor ions were subjected to collision-induced dissociation with argon
as the collision gas. LIFT mode was used to analyze all fragment ions in single
sweep, and data were processed with Flex Analysis software.
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II.8. Molecular Dynamics (MD) Simulations
To compare K49’s property with all lysine residues on this rhuMAb A,
molecular dynamics simulations were performed to analyze the movements of lysine
residues by calculating their motions in aqueous solution. Based on the IgG1 protein
framework, a generic model was built which includes common intra-molecule forces
for a MAb. rhuMAb A’s particular protein amino acid sequence was applied to this
model to generate a molecule specific 3D structure in aqueous solution. Lysine’s
solvent accessible surface area (SASA) was determined by AREAIMOL (CCP4
supported Program), which is based on a “rolling ball” algorithm (Lee, B., and
Richards, F.M., 1971). This algorithm uses a sphere of water as a particular radius to
‘probe’ the surface of the rhuMAb A molecule then calculate the exposure area of a
particular lysine.
Furthermore, molecular dynamics was applied to determine the lysine’s local
environment via a computer simulation of physical movements of atoms and
molecules. In a given time, the atoms on this rhuMAb A were allowed to interact
with and move in the aqueous solution, resulting a view of the motion of the atoms.
In these simulations we performed explicit water (with 11780 water molecules)
molecular dynamics (MD) simulations of a set of FAb fragments and calculated
different properties. Focus was placed on lysine residues to identify the properties of
lysine residues which might correlate to experimentally observed glycation
formation propensities in rhuMAb A. This approach is different from the empirical
methods discussed above, because we calculated dynamic properties of the protein
that could not be determined from the static structure.
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Throughout these simulations, the temperature was kept constant by coupling
the system to a temperature bath of 300 K using simulation algorithm (Bussi, G.,
Donalido, D., Parrinello, M.,
unprotonated.

2007) at pH7.4. Histidines on rhuMAb A were

During equilibration, the volume was initially kept constant by

coupling the system to a pressure bath at 1.0 atm (Bernedsen, H.J.C., Postma, J.P.M.
et al. 1984). Following equilibration, the simulations were kept at constant pressure.
Following equilibration, a set of trajectories with 75ns duration was performed.
Trajectories from MD simulations were then analyzed with various tools available in
AMBER program suite. (Case, D.A. et al. 2005)
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III. Results
III.1. Boronate Affinity HPLC
We determined total glycation level of rhuMAb A by using boronate affinity
chromatography (BAC).

Boronate affinity chromatography is based on the

formation of a five- member ring structure between a sugar’s cis-hydroxl groups and
boronate ion’s negative charge on the column (Figure 2-1). The affinity to sugar
ensures boronate capture the glycated protein under alkaline condition. After loading
onto a boronate affinity column, protein samples were eluted with a gradient of a
competing sugar, sorbitol.

Unglycated proteins were eluted at ~2.4 min, while

glycated proteins were detected at ~25 min. The elution conditions used here did not
provide resolution of proteins with different sugar to protein ratios. Therefore, the
overall glycation level was defined as percent peak area of the retained peak on
boronate affinity chromatograms.
From this study result, glycated rhuMAb A from a regular glucose batch feed
process (batch feed protein to glucose concentration, 1.5g/L titer: 8g/L glucose feed)
was 42.0% based on the integration of the retained peak area, as shown in Figure 22a.

This indicates 42% of rhuMAb A contained at least one glucose addition

modification per protein. In comparison, under forced glycation condition (24 hours
incubation with 1.2M of glucose in 20mM sodium phosphate, pH 7.4 at 37°C), this
rhuMAb A was nearly fully glycated, such that 99.3% of the rhuMAb A contained at
least one glycation modification (Figure 2-2 b).
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III.2. RP-HPLC-ESI/MS
Because BAC cannot determine the glucose to protein ratio, Electron Spray
Ionization/ Mass spectrometry (ESI/MS) was applied to determine the approximate
numbers of glucose per rhuMAb A on the forced glycated rhuMAb A sample. In
order to measure the mass, rhuMAb A was reduced, then separated into light chains
and heavy chains on reverse phase chromatography. The eluted chromatography
fractions went through an ESI/MS mass analyzer. Molecular mass of the light chains
and the heavy chains species were determined individually. As shown in Figure 2-3,
four species with different molecular weights were detected in the mass profile of the
fully glycated rhuMAb A light chains. They ranged from no glucose to a maximum
of three glucoses per light chain. The majority of glycated light chains contained
only single glycated specie. For glycated heavy chains, as shown in Figure 2-4, three
different heavy chain glycation species were observed. They ranged from no glucose
to a maximum of two glucoses addition per heavy chain. The majority of heavy
chains were native species containing no glucose modification. It is notable that the
most abundant glycation was found on the light chain of rhuMAb A.

III.3. Tryptic Peptide Map
The next question to be answered was which amino acid sites on the primary
sequence level were glycated. Identification of the glycated amino acid sites was
attempted by tryptic peptide mapping. Tryptic peptides were generated by enzymatic
digestion of rhuMAb A. The digested peptide fragments were separated on RPHPLC, resulting in a unique peptide elution profile of each protein faction
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(unglycated and glycated fractions) from BAC. By comparing peptide-map profile of
the glycated and unglycated samples, glycated peptide fragments were detected.
MS/MS analysis was performed on the putative glycated peptide fragments to assign
the peptide sequence and identify the amino acid site of modification.

Table 2-1

summarizes the glycation level of amino acid sites that were glycated under forced
glycation condition. There were a total of seven amino acid sites on rhuMAb A that
had various levels of susceptibility to glycation. It is notable that light chain lysine
49 (K49) was the primary amino acid site modified by glycation, where 90% of this
particular residue on rhuMAb A was glycated. The next most glycated site was the
heavy chain N-terminal, glutamic acid’s alpha amino group, with 5% glycated only.
All the other sites were glycated at very low levels, less than 5% modified. This sitespecific result agrees with published work on non-forced glycation of rhuMAb A by
Zhang, et al . ( Zhang, B. et al . 2008).

III.4. Understanding The Cause of Site Specific Glycation by Molecular
Dynamic (MD) Simulations
What special property does K49 have that allows such a high extent of
modification by glycation? Does it happen to be more solvent accessible, which
increases the probability of reaction with glucoses? Or is there a special local
electrostatic environment?
The solvent accessible surface area (SASA) of each lysine residue was
determined using AREAIMOL calculation. The summary of average SASA on each
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lysine residue is shown in Table 2-2. It is notable that K49 was not the most solvent
accessible lysine residue on rhuMAb A.
Also, the local environment of glycated lysine residues, especially the
potential aspartate to lysine pairing effect, was evaluated. There were three major
results: the average distance between D31 to K49 was 11.8Å, which agrees with
Zhang’s report. However, D31 to K49 is not the only spatial adjacent (D:K) pair in
rhuMAb A. There were five other (D:K) pairs of a distance ~5.5 Å. Interestingly,
only two of the five lysine residues were glycated. More importantly, lysine K49 was
surrounded by three aspartates.

They were light chain D30, D31 and another

aspartate on heavy chain, D105. D30 and D31 had similar spatial distance to K49.
However, the D105 was only 5.4 Å to K 49, a much closer spatial distance than D30
or D31 had (Figure 2-6). These three aspartate residues also had different solvent
accessible surface areas. As shown in Table 2-3, D30 and D31 had the highest SASA
value among all aspartate residues that were paired with lysine residues. On the other
hand, D 105 had the lowest SASA value.

IV. Discussion
From the characterization study result, in vitro forced glycation can
successfully produce a nearly 100% glycated rhuMAb A.

The ESI/MS result

indicated that the forced glycation of rhuMAb A forms a heterogeneous mixture,
with different extents of glucose modification. To understand the complexity of the
fully glycated rhuMAb A, we calculated the possible glucose to rhuMAb A ratio,
based on different scenarios of glucose modification on light chains and heavy
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chains. By combining possible glucose ratio on both heavy chains and both light
chains, we estimated that the average intact rhuMAb A may contain from one to ten
glucoses per molecule, with the majority containing at least one glucose on the light
chain.
The forced glycation model of rhuMAb A was also proven to mimic the site
specific glycation in typical cell culture conditions, meaning the most susceptible
glycation site is still light chain lysine, K49. Since this forced glycation model
provides high abundance of glycated rhuMAb A in a much rapid manner than a 1014 day cell culture, it becomes a great tool to investigate site specific glyation
reaction on MAbs and proteins.
In the past, researchers had shown that glycation specificity is not governed
by the pKa of an amine group, rather by the internal micro-environment of a protein.
Neighboring amino acids can often involve a catalyst effect. Watkins, et al. first
reported specificity of glycation on RNase in 1985. They reported that certain lysine
residues, especially the ones close to the RNase active site, were easy to be glycated.
On the other hand, the surface lysine residues were relatively inactive. Watkins also
proposed that both the Schiff base equilibrium concentration and the rate of Amadori
rearrangement at lysine residues were important in determining the specificity of
RNase glycation (Watkins, N.G. et al. 1985 and 1987). For site specific glycation in
MAbs, Quan, et al. had observed histidine presence near a lysine residue, and
proposed that a histidine residue may act as a proton transfer which could help to
glycate nearby lysines (Quan, C. et al. 2008).
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In the case of rhuMAb A glycation specificity, Zhang’s group proposed an
aspartate catalyst effect in 2008. The proposed mechanism was based on intensive
mutation work, suggesting that light chain aspartate D31 is the essential catalyst for
K49 site-specific glycation phenomenon. However, even with mutations of D31 to
other amino acids, such as threonine, lysine K49 was still glycated to a relatively
high level, ~ 25% compared to ~ 40% before mutation . Since Zhang’s estimation of
spatial distance of D31 and K49 was based on static crystal structure, it does not
represent the lysine residue’s activity and movement in a dynamic liquid
environment.
In our study, molecular dynamics was used to evaluate K49’s dynamic
motions in aqueous solution. Two parameters were calculated 1) solvent accessible
surface area, and 2) the distance between aspartate residues and lysine residues on
this rhuMAb A’s Fab region.
The presented work demonstrated: Lysine K49 does not exhibit the highest
solvent accessible surface area (SASA) compared with other lysine residues. Rather
K49 is on the lower rank of exposed lysine residues, indicating that site-specific
glycation on rhuMAb A is not determined by solvent accessibility. Among five
lysine residues, which have aspartate spatially close to them, only two lysines (K49
and K75) were significantly glycated. This indicates that the presence of aspartate
near by lysines does not necessarily catalyze glycation either. Finally, a total of three
aspartates are thought to be involved in K49 microenvironment. However, the
distances and angles between these aspartate residues and

K49 do not favor

formation of hydrogen bond. D30 and D31 are located 11 Å from K49, which is too
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far to form hydrogen bonds with K49. D105 is only 5.3 Å from K49, which is still
too far to form a hydrogen bond. Therefore, it is unlikely that these aspartate residues
react or bond to lysine K49 directly to promote glycation. Instead, the three aspartate
residues together are thought to provide a strong electron-donating environment
around K49 at physiological pH.
How would this catalysis work? Do the aspartate residues directly react with
glucose rather than lysine? We are inspired by knowledge learned from nature,
especially the enzymatic mechanism of two enzymes in sugar metabolism: Aldose B
and Triose phosphate isomerase. Aldose B has an active site involving an aspartate
residue D33, and a lysine residue K229. These two residues act as mediators to
shuttle the electron on the carbonyl group and the hydroxyl group on sugar. (Cox,
T.M. 1994 ; Garrett, R.H and Crisham, C.M., 2010). Triose phosphate isomerase also
contains a basic glutamate residue E165 and an acidic proton-donating histidine
residue H95 to convert the –CHO aldehyde to a –C=O ketone group of sugar (Harris,
T.K. et al. 1998). These two enzymes both use an electron donating rich residue
(aspartic acid, glutamic acid) that are negatively charged (aspartate, glutamate) at
physiological pH, to help extract a proton from hydroxyl group on sugar. At the
same time, an acidic proton-donating residue (lysine, histdine) donates a proton to
sugar’s carbonyl group, resulting in conversion of carbon one's carbonyl group to a
hydroxyl group. These reactions are also essential steps for glycation Schiff base
formation and Amadori rearrangement as well.
With the knowledge obtained from mechanisms of sugar metabolism
enzymes, we hypothesize that D30, D31 and D105 work cooperatively around K49
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to promote K49 glycation in two steps. First, by creating a negatively charged
microenvironment, D30, D31 may act as a porter to attract glucose and keep glucose
in the vicinity close to K49. D30 or D31, that has high solvent accessible surface
area, withdraws the hydrogen from carbon two in glucose. The hydrogen withdraw
causes carbon two to carry a negative charge and carbon one to carry positive charge.
At physiological condition pH 7.4, K49 is unprotonated, allowing it to attack the
carbon one, assisting in the formation of a Schiff base. Once a Schiff base is formed,
the extra aspartate D105, which is close to K49, may be involved in further electron
transfer, by shifting an electron of the C=N double bond on carbon one to the C=O
double bond on carbon two, to form a ketone. This is assisting the Amadori
rearrangement. Thus, the high abundance of K49 glycation observed on rhMAb A
may be a consequence of two sequential steps, catalyzed by neighboring aspartate
residues
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V. Conclusions
The unique site-specific glycation of rhuMAb A makes this rhuMAb A a
valuable model protein to study IgG structure modification by glycation. Several
conclusions can be made from this study.
1) The forced glycation model is successful to analyze glycation modification from the
whole protein level to the primary amino acid level.
2) The forced glycated rhuMAb A molecule is shown to be a mixture of species with
various levels of glycation with complex structure modification.
3) Site-specific glycation on K49 is not due to spatial proximity of D31. Instead, a
strong electron-donating environment created by three near by aspartates: D30, D31,
and D105 may facilitate K49’s specific glycation.
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Figure 2-1: Schematic illustration on boronate affinity resin reacts with
carbohydrate’s cis-diol group.
a) boronate carries a negative charge under alkaline condition.
b) Cis-diol group forms a five-member ring with boronate by dehydration then
retains on resin.
Reference from: Li, A., Pfuller, U., Larsson E.V., Jungvid, H., Galaev, I.Y.,
Mattiasson, B. (2001). Separation of mistletoe lectins based on the degree of
glycosylation using boronate affinity chromatography. Journal of
Chromatography A. 925 , 115-121.
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Figure 2-2: Boronate affinity chromatograms of rhuMAb A.
a) rhuMAb A from regular batch feed process.
b) Forced glycated with 1M glucose in phosphate buffer pH 7.4 for
24hours at 37°C in vitro.
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Figure 2-3 : ESI-MS measured the molecular mass of glycated rhuMAb
light chain. Four molecular weight peaks were detected:
a) native light chain mass 23286 dalton/mol;
b) one glucose added light chain with mass 23448 dalton/mol;
c) two glucose added light chain with mass 23610 dalton/mol;
d) three glucoses added light chain with mass 23772 dalton/mol.
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Figure 2-4: ESI-MS measured the molecular mass of glycated rhuMAb A
heavy chain.
Three molecular weight peaks were detected:
a) native heavy chain mass 48790 dalton/mol;
b) one glucose added heavy chain with mass 48952 dalton/mol;
c) two glucoses added heavy chain with mass 49114 dalton/mol.
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Spatial distance between aspartate to lysine

Time ( nano sec)
Figure 2-5: Graph of spatial distance (between aspartate residues to
lysine residues) vs. time over 75 nanoseconds by molecular
dynamics simulations.
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LC D30, D31
HC
D105

LC
K49

Figure 2-6: Illustration of MD simulated locations of K49, D30,
D31 and D105 on rhuMAb A’s Fab region.
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Table 2-1: Summary of glycation level on primary amino acid sites of
rhuMAb A’s light chain and heavy chain.
Glycation modification extent was measured by tryptic peptide map.
Glycated
(%)

Modified amino acid
sites

LC-K49

90.5

LC-K149

0.9

HC-K64

0.5

HC-K75

2.2

HC-K133

0.5

HC-E1
(heavy chain
N-terminal)

4.9

LC-D1
(light chain
N-terminal)

0.3
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Amino Acid
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS
LYS

Heavy Chain or
Light Chain
HC
LC
HC
HC
LC
LC
HC
HC
LC
HC
HC
LC
LC
HC
LC
LC
LC
HC
LC
LC
LC
LC
HC
HC
LC

Solvent Accessible
Surface
Area
( Å2)
148.572
144.434
127.637
124.482
124.274
121.164
116.242
114.802
113.749
111.675
110.161
109.156
107.675
93.7401
93.4605
92.3458
90.6972
90.5255
85.7253
68.0554
67.3747
63.3898
57.2227
50.0781
48.2433

#
222
169
205
210
145
126
64
43
42
75
133
188
190
214
45
107
183
121
207
103
39
49
218
213
149

Table 2-2: Solvent accessible surface area of
all the lysine residues on rhuMAb A.
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Detected
Glycation

+/0.5%
+/2.2%
+/0.5%

+ /90.5%
+/0.9%

Lysine
Position

Aspartate
Position

LC K49
LC K49
LC K49
LC K188
HC K75
HC K218
HC K222

LC D30
LC D31
HC D105
LC D185
HC D72
LC D122
LC D122

Average
Distance
(Å )
11.8
11.8
5.3
5.3
5.5
5.5
5.5

Detected
Lysine
GLycation
+
+
+
+

Aspartate
SASA
70
77
33
63
44
85
85

Table 2-3: Summary of lysine to aspartate pairs with average
spatial distance between lysine and aspartate.
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Abstract
An in vitro forced glycation model was applied to evaluate glycation product
stability, degradation pathway, and the degradation products of glycated rhuMAb A.
During an accelerated stability study, upon thermal stress at 40°C for four weeks,
glycated rhuMAb A went through two reactions: hydrolysis of glycation adducts
(Schiff base and Amadori product) and formation of advanced glycation products.
While hydrolysis reaction was more pronounced than the AGEs formation. Kinetically,
it was found that hydrolysis of glycation adduct continued for four weeks, but AGEs
formation plateaued after one week. The overall combination of both reactions caused
glycated rhuMAb A to lose affinity to boronate resin, with a first order reaction rate. A
set of analytical characterization on final degradation products structures was
performed. The results demonstrated that the unglycated form of rhuMAb A, which
was generated by hydrolysis of glycation site at K49 is the main final degradation
products after thermal stress. This observation agreed with kinetic observation that
reverse hydrolysis of both the Schiff base and Amadori product is the main degradation
pathway of glycated rhuMAb A at 40°C in pH 6.5 phosphate formulation buffer. The
reversibility of glycation adduct on K49 may be catalyzed by adjacent aspartic acids.
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I. Introduction
The common manufacturing process of a MAb involves production in
mammalian chinese hamster ovarian cells (CHO) by cell culture for 10-14 days.
During this process a MAb is expressed in CHO and secreted into the cell culture
medium, which contains glucoses, where the MAb can undergo glycation. Thus the
purified MAb contains a certain level of glycation (Quan, C. et al. 2008, Zhang, B. et
al. 2008). Several studies have been performed to understand the cell culture
conditions that control the total glycation level (Yuk, I.H. et al. 2011). However,
little knowledge is available regarding impact of glycation on most final purified
MAbs. In particular, the stability and degradation pathway of glycation adducts under
pharmaceutical drug product conditions are not well understood. This is due to wide
distribution of glycation sites on a large protein, low level of glycation on each site,
and lack of a robust analytical technology capable of quantify glycation level and
changes.
As described in previous study (Chapter 2) , a forced glycation rhuMAb A
model was developed and shown to be a successful tool to evaluate amino acid
susceptibility to glycation. Fully glycated rhuMAb A was produced from this
accelerated in vitro model. This highly glycated product provides an opportunity to
understand the glycation adduct’s degradation pathways and to perform further
structural characterization.
The glycation reaction has multiple steps and produces multiple intermediate
species. The end-product may differ based on pH and electrostatics of the local
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environment (Figure 3-1). The initial linkage between a glucose molecule and a
protein molecule forms a Schiff base. The Schiff base (aldimine) formation is a
readily reversible reaction by hydrolysis. Schiff base also can rearrange to a more
stable Amadori (ketoamine) product under high pH (Amadori, W. et al.1931). The
ketone-containing Amadori product can further react with another free amino group
in the surrounding environment to form advanced glycation end products, AGEs.
Researchers have extensively investigated the reactions involved in
continuous exposure of glycated protein to reducing reagents to mimic the protein’s
modification in human body under in vivo chronic condition. Studies have
demonstrated that the formation of AGEs is markedly accelerated with an increased
availability of reducing sugars (Dutta, U. et al. 2005). One question that remains
unanswered is, can AGEs formation be initiated on MAbs under the common
pharmaceutical storage conditions in the absence of reducing sugars in the
formulation?
The forced glycation model for rhuMAb A described in previous study was
implemented to investigate the stability and degradation pathways of glycated
rhuMAb A under pharmaceutical storage conditions. To understand the destiny of
Schiff base (aldimine) and Amadori product (ketoamine), we focused on glycation
adduct stability in formulation buffer in the absence of exogenous carbonyl reagents.
An accelerated stability study of glycated rhuMAb A upon thermal stress was
performed. The samples were incubated at 40°C for 4 weeks at pH 6.5 in 20 mM
sodium phosphate. The total level of glycation adduct (% protein glycated) was
monitored by boronate affinity HPLC (BAC) with UV detection at 280 nm as
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previously described. In addition, the glycation adduct’s glucose to protein ratio was
monitored under reduction conditions by LC-ESI/MS. Fluorescence spectroscopy and
BAC with fluorescence detection were used to monitor the formation of AGEs upon
thermal stress. The total amount of AGEs was measured via quantification of overall
polyclonal antibody binding to different AGEs species. Relative intensity of AGEs
during a thermal stability study was reported.
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II. Experimental
II. 1. Materials and Reagents
A regular lot of rhuMAb A (27 mg/mL, PBS buffer, pH 7.4) bulk material
was obtained from Genentech. Trypsin, sequencing grade (TPCK treated), was
purchased from Promega (Madison, WI), and Peptide:N-glycosidase F (PNGase F)
from New England BioLabs Inc (Ipswich, MA). N-(2-Hydroxyethyl) piperazine-N¢(3-propanesulfonic acid) (EPPS; 99.0%) and dithiothreitol (DTT; ultrapure) were
obtained from USB Corp. (Cleveland, OH). D-Sorbitol (minimum 98%), R-Dglucose

(ACS

reagent),

iodoacetic

acid

(IAA;

_99%),

and

R-cyano-4-

hydroxycinnamic acid (CHCA) were procured from Sigma-Aldrich (St. Louis MO).
HPLC grade acetonitrile (ACN) and methanol were purchased from Fisher Scientific
(Fair Lawn, NJ). Water used in all experiments was obtained from a Milli-Q Plus
purification system (Millipore, Bedford, MA).
II.2. In Vitro Glycation of rhuMAb and Stability
The rhuMAb A in PBS buffer, pH 7.4, was further glycated in vitro. rhuMAb
A was buffer exchanged into incubation buffer with dialysis prepared in a 15 ml
cassette with 10kD membrane. Final in vitro glycation solution contains 50mg/ml
rhuMAb A with 1200 mM, D-glucose, in 20 mM sodium phosphate buffer, pH 7.4.
The in vitro glycation solution was kept in an incubator at 37 °C for 24 h. The
reaction mixtures were submitted for immediate buffer exchange using a 15 ml
dialysis cassette with 10kD membrane into phosphate buffer, pH 6.5. After
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conditioning with trehalose and surfactant, glycated rhuMAb A was formulated as
20mg/ml in 20mM sodium phosphate with 8% trehalose and 0.04% polysorbate 20.
Glycated rhuMAb A was sterile filtered and filled into 2 cc glass vials, with 1
ml of solution in each vial. The stability study was set up at 40°C for 4 weeks with
two vial replicates per week. At each time point, samples were pulled then stored at
-70°C until analysis

II.3. Boronate Affinity HPLC (BAC)
Early stage glycation adducts can often be identified by a Boronate HPLC
method using A TSK gel boronate 5PW column 7.5x75mm. The BAC mobile phase
A was 50mM EPPS, 10mM Tris, 200mM NaCl, at pH 8.7, and BAC mobile phase B,
was 500mM sorbitol in mobile phase A. The mobile phase flow rate 1 mL/min and
the column temperature were maintained at 40°C with both UV and fluorescence
detecto0sr. The gradient for HPLC elution was optimized for this rhuMAb A.

II. 4 Enzymatic Digestion of rhuMAb A
Several enzymatic treatments were performed on rhuMAb A samples before
they were analyzed for reverse phase-HPLC, or mass spectrometric analyses, to
determine the amino acid sequence and structural integrity of rhuMAb A.
PNGase F Treatment. PNGase F was used to remove the oligosaccharides
in the Fc portion of a MAb. The rhuMAb A samples were buffer exchanged into
50 mM Tris buffer, pH 7.5, using a NAP-5 column. The protein concentration was
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adjusted to 2.5 mg/mL. PNGase F was added in an enzyme-to-substrate ratio of
1:600 (w/w). The digestion was performed at 37°C overnight (15 h).
Tryptic Digestion. Prior to tryptic digestion, rhuMAb was reduced with DTT
and then alkylated with IAA. Typically, 250 µL of antibody sample (2 mg/mL) was
mixed with 20 µL of 1 M DTT in 730 µL of 6 M guanidine, 50 mM Tris, pH 8.0.
The mixture was incubated at 37 °C for 1 h. It was then cooled to room temperature,
and 50 uL of 1 M (IAA) in 1 M NaOH was added for carboxymethylation. The
alkylation reaction was incubated at room temperature in the dark for 15-20 min.
The residual IAA was quenched by the addition of 10 µL of 1 M DTT. The reduced
and carboxymethylated rhuMAb A was then buffer exchanged into the digestion
buffer, which contained 25 mM Tris, 1 mM CaCl2, pH 8.3, using a PD-10 column
(Sephadex G-25 medium, GE Healthcare). Trypsin was added at an enzyme-tosubstrate ratio of 1:50 (w/w). The solution was mixed briefly and incubated in a
37°C water bath for 5 h. The digestion was terminated by adding 0.3% (v/v)
trifluoroacetic acid (TFA) to the solution. The digest was then stored at -70°C until
analysis.

II.5. Reverse Phase-HPLC with Electron Spray Ionization/ Mass Spectroscopy
(RP-HPLC-ESI/MS)
The molecular masses of the intact, PNGase F-treated, and reduced rhuMAb
A samples were determined by using a LC/ESI-MS setup. AnAgilent 1090 HPLC
system was coupled with a PE Sciex API 3000 electrospray ionization triplequadrupole mass spectrometer (Applied Biosystems, Foster City, CA). The samples
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were desalted by reverse phase –HPLC (RP-HPLC) using a capillary column
(Poros R1, 0.33 x 200 mm) equilibrated at a flow rate of 200 uL/min with 0.2%
formic acid (solvent A) at a column temperature of 40°C. Samples were eluted
using a linear gradient from 25% solvent B (0.2% formic acid in acetonitrile) to
70% solvent B over 16 min. The elutant from the RP-HPLC column was directed
into the mass spectrometer operating in the positive ion mode. For post-reduction
analysis, samples were incubated in 25 mM DTT for 15 min at 37°C prior to
LC/MS analysis.

II.6. Tryptic Peptide Mapping
Peptides profiles of tryptic-digested rhuMAb A were analyzed by an RPHPLC using a Jupitor C18 2.0x250 mm column at 45°C and UV detection at
214nm. The flow rate was 0.25ml/min, in mobile phase A: 0.1% TFA in water and
B: 0.09% TFA in acetonitrile. The gradient was optimized for rhuMAb A. By
comparing the peptide maps of time zero and stressed glycated rhuMAb A, the
distinctive peptide fractions on degraded glycated rhuMAb A were collected for
further characterization by MALDI-TOF MS/MS sequencing.
II.7. Protein Chip Matrix Assisted Laser Desorption Ionization- Time-OfFlight mass spectrometry (MALDI-TOF)
Isolated tryptic peptides were spotted individually on a SCOUT 384 multiprobe plate with a CHCA matrix and analyzed in the positive mode using a Bruker
Ultraflex-I MALDI-TOF-TOF mass spectrometer (Bremen/Leipzig, Germany).
Sele8cted precursor ions were subjected to collision-induced dissociation with
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argon as the collision gas. LIFT mode was used to analyze all fragment ions in
single sweep, and data were processed with Flex Analysis software.
II. 8. Fluorescence Spectroscopy
Fluorescence emission spectra were measured using a Fluoromax-4 spectrofluorometer by Horiba Jobin Yvon ( Edison NJ, USA). The excitation wavelength
was 350 nm, emission wavelength was 440nm. A circulating water bath set at 25 ±
1°C controlled the sample cell temperature during the measurements. Both
spectrometric analyses were performed using cuvettes (12.5 × 12.5 × 36 mm) from
Fisher Scientific (New Lawn, NJ, U.S.A.).

II.9. Total AGEs Enzyme-linked Immunosorbent (ELISA) assay
AGEs ELISA is an enzyme immunoassay for rapid detection and
quantification of AGEs-protein adducts. The quantity of AGEs adducts in protein is
determined by comparing absorbance of protein sample with that of a known AGEBSA standard curve.
An AGEs-ELISA kit and BSA were purchased from Cell Biolabs. A layer of
anti-AGE polyclonal antibody was plated in the 96 well. 100ul of protein samples
were diluted in serial dilution then adsorbed on to 96-well plate for 1 hour at room
temperature on an orbital shaker. The AGE protein adducts generated by rhuMAb A
from thermal stress present in the sample were probed and bound with anti-AGE
polyclonal antibody. After incubation, buffer three cycles of buffer wash were
performed with 250 ul phosphate buffered saline (PBS) buffer on each well. Excess
solution was removed after each wash. 100 ul of Anti-HRP conjugated secondary
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antibody were added into wells and incubated for 1hour at room temperature on
orbital shaker, allowing the secondary antibody binds to the rhuMAb A. The antiAGEs complex plate was wash for five times with 250ul wash buffer. Substrate
solution was warmed up to room temperature, then 100ul was added to each well and
incubated for 10 min on an orbital shaker. The enzymatic reaction was stopped by
stop solution. Absorbance of each well was measured on a micro-plate reader using
450nm as the primary wave length. The AGE protein adduct content in the unknown
sample was determined by comparing with standard curve of by AGE-BSA standard
(Cell Biolabs product manual).

III. Results
III.1. BAC
The thermally stressed samples exhibited a rapid loss of total glycation level
over 4 weeks at 40°C, as shown in Figure 3-2. The glycation level dropped from
98.5% at initial time, to 69.6% after one week, 60.5% after two weeks, and 32.8%
after four weeks. The decrease of glycation is a linear plot on natural log vs. time,
indicating this is a first order reaction for glycation loss (Figure 3-3).

III.2. LC-ESI/MS
The decrease of glycation can occur because of the Schiff base reversibility,
that resulting in a loss of glucose or formation of AGE products that alter the cishydroxal structure. Reduced ESI/MS analysis confirmed the glucose loss on both
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light chains and heavy chains (Figure 3-4). No new mass species were detected on the
mass spectrometry profile besides known glycated and un-glycated rhuMAb A peaks.
Most importantly, there was an obvious change on light chain mass spectrometry
profile. The glycated light chain intensity decreased after thermal stress, while the
un-glycated light chain peak intensity increased.

Unglycated rhuMAb A finally

became the main light chain peak in mass spectrometry profile (Figure 3-4). This
indicates most glycated light chains went to the unglycated form, demonstrating the
reversibility of glycation modification under the thermally stressed condition at pH
6.5.

III.3. Fluorescence Spectroscopy and BAC
While thermal stress reduced the amount of glycation, can it also introduce
more advanced glycation products? Formation of pentosidine-like AGEs can be
measured by fluorescence spectroscopy at excitation 350nm/emission 440 nm (Dutta,
U. et al. 2005). After thermal stress, fluorescence spectroscopy and boronate affinity
chromatography with fluorescence detection, were utilized to monitor fluorescent
AGEs. Fluorescent analysis was performed on bulk property for solution of glycated
rhuMAb A at 1 mg/ml (Figure 3-5). The result showed a jump of emission intensity
between initial time zero and one week after thermal stress. After one week the
relative emission intensity plateaued out. This indicates the formation of pentosidine
like fluorescent AGEs occurred rapidly and stabilized after one week.
Fluorescence traces on BAC showed two peaks with fluorescent signal at
350/440nm (Figure 3-6). Peak 1, at retention time 2.4 min, overlapped with
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unglycated rhuMAb A. Peak 2, at retention time 2.7 min, is a new peak formed upon
thermal stress (Figure 3-6). The intensity of both peaks increased during the thermal
stress, peak 1 being the major peak. However, the total peak area based on
fluorescence signal was very low, making it hard to quantify the exact amount of
AGEs. Figure 3-7 shows the comparison of the UV and fluorescence signals in flow
through portion on BAC, while the fluorescence signal increased linearly with time,
the size of the peak at 280nm increased. This was due to the continuous increasing
amount of rhuMAb A in the flow-through portion. After normalizing the fluorescence
peak area by the protein amount, the normalized fluorescence signal/protein amount
is consistent with spectroscopy measurements, the amount of AGEs detected on
BAC increase in the first week of thermal stress, then plateaued (Figure 3-8).
Therefore, BAC with tandem-UV 280nm - fluorescence 350/440nm detection is
capable of monitoring both glycation level change and AGEs formation.

III.4. Peptide Mapping
What are the degradation end-products of the amino acid level after thermal
stress? The possible degradation products from thermally stressed, glycated rhuMAb
A were studied using tryptic peptide mapping. By comparing the time zero control to
thermally stressed samples, several peptide fragments were found after thermal
degradation, shown in Figures 3-9 and Figure 3-10. Due to the protein fragmentation
in MS analyzer, pentosidine-like AGEs may have been destroyed; the amino acid
modification by peptide map MS/MS analysis did not detect or quantify any
pentosidine-like AGEs. Table 3-1 summarizes the degradation products on each
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glycated amino acid site. The MS/MS analysis on these peptides identified two major
degradation products. One is the non-fluorescent AGE: carboxyl-methyl lysine (CML)
modified peptides which eluted around 40 min on peptide map (Figure 3-9). The
other is the unglycated rhuMAb A, which eluted around 79 min (Figure 3-10). The
presence of these two products confirms that glycated rhuMAb A underwent both
pathways: reversal of glycation and formation of advanced glycation endproducts.
The abundance of unglycated rhuMAb A was greater than that of the CML modified
rhuMAb A. It is notable that majority of glycation reversal occurred on K49, other
glycation site appeared to be more stable, maintaining consistent glycation levels after
thermal stress.

III.5. Total AGE ELISA
AGE ELISA is based on binding of a family of polyclonal antibodies against
AGEs. Total AGEs was measured by using polyclonal antibodies to capture variety of
different AGEs structures, including fluorescent structures and non-fluorescent
structures (Figure 3-11). The ELISA result showed an increase of relative intensity of
AGEs upon thermal stress. This confirmed AGEs formation during the 40°C
incubation. The increasing trend was similar to fluorescence and BAC results, where
a rapid AGEs formation was detected in the first week then plateaued (Figure 3-12).
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IV. Discussion
Degradation pathway of glycated rhuMAb A
The thermal stability study demonstrated that glycated rhuMAb A can
undergo two possible parallel reactions (Figure 3-13). The glycated rhuMAb A either
reverses back to the unglycated rhuMAb A, or moves forward to form AGEs. It is
important to note that 1) the glycation adduct hydrolysis reaction is more pronounced
than the AGE formation, and 2) glycation adducts hydrolysis continued for four
weeks, but AGEs formation plateaued after one week. What could be the scientific
rationale behind these observations?
Amadori rearrangement is favored at pH greater than pH 7.0, where the C=N
double bond can shift to a C=O double bond. At pH 6.5, the rearrangement from
Schiff base to Amadori product is not at the optimum condition, and the most of
early glycation adducts should be in the Schiff base form. Since the Schiff base is
thermodynamically unstable in liquids at neutral pH, the hydrolysis reaction is
favored. Thus, the reversal to unglycated amino acid on protein is the predominant
reaction and it proceeds towards completion. Second, the amount of carbonyl groups
(C=O group) in Amadori products restrained further reaction to advanced glycation,
because advanced glycation needs continuous attack of carbonyl group to amine
group. Without additional free glucose in the formulation, the only carbonyl group
available to initiate further advanced glycation reaction is the ketone in Amadori
products or its degradation bi-carbonyl products. Since amount of precursor Amadori
product is limited, the amount of ketone carbonyl available for advanced glycation
reaction is also limited. In addition, the ketone group in the Amadori product is less
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reactive than the regular aldehyde group in free glucose. Therefore, under the studied
pharmaceutical storage condition, the total amount and reactivity of carbonyl groups
were limited, and the AGEs formation reaction is not the dominant reaction. This is
why AGEs formation reached plateau after one week.

AGEs Structures
The low level AGE products formed after thermal stress was confirmed to be
a mixture. The fluorescent pentosidine-like ring structures and straight chain CML
structures were both indentified (Figure 3-14). However, due to the limitations of
analytical methods, it is not possible to quantify the exact amount of fluorescent
pentosidine-like AGEs, or to further characterize their structures. The straight chain
CML can be identified and quantified by peptide map with MS/MS analysis. CML
was less than five percent of the final degraded rhuMAb A.

Degradation at Modified Sites
Although we did not study the glycation loss of each site during thermal stress
kinetically, the glycation reversibility of each site can still be evaluated, based on the
final glycation level at each site that were summarized in the Table 3-1.

K49 and

heavy chain N terminal had the highest glycation level initially, but these two sites
also have the most rapid reversibility of glycation adduct. As we described in Chapter
2, three aspartic acids catalyze the glycation on K49. Based on catalyst nature of the
K49 microenvironment, the nearby aspartic acids can also facilitate the reverse
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reaction: hydrolysis of glycation adducts. The reason for glycation reversal on the
heavy chain N –terminal is yet to be known.

77

V. Conclusions
The unique site specific glycation nature of rhuMAb A makes it a great
candidate to study MAb structure modification by glycation and glycation adduct
stability. The following conclusions can be drawn from the studied performed:
1) The forced glycation model is successful to analyze glycation chemical
modification on whole protein levels and primary amino acid levels.
2) BAC with tandem-UV 280- fluorescence 350/440nm method is a great tool to
monitor both glycation level change and AGEs formation.
3) Upon thermal stress, the forced glycated rhuMAb A showed a rapid and
continuous hydrolysis reaction, and a slow and limited advanced glycation reaction.
The overall combination of both reactions caused glycated rhuMAb A to lose affinity
to boronate resin with a first order reaction rate.
4) The structure analysis of final degradation products agreed with kinetic
observation that reversibility of Schiff base is the main degradation pathway of
glycated rhuMAb A at 40°C in pH 6.5 phosphate formulation buffer.
5) Reversibility of glycation adduct on K49 is catalyzed by its adjacent aspartic acids.
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Figure 3-1: Chemistry of glycation reaction and advanced glycation reaction .
Reference:
Munch, G., Thome, J., Foley, P., Schinezel, R., Riederer, P. Advanced glycation
end products in aging and Alzheimer’s disease Brain Research Reviews 1997,
23,134-143.
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Figure 3-2: Boronate affinity chromatograms showed that glycation level
dropped during thermal stress on fully glcyated rhuMAb A at 40°C over
4weeks.
a)
b)
c)
d)

at control t0 rhuMAb A is 98.5% glycated;
at 1week 40°C rhuMAb A is 69.6% glycated;
at 2weeks 40°C rhuMAb A is 60.5% glycated;
at 4weeks 40°C rhuMAb A is 32.8% glycated.
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Figure 3-3: Plot fitting of ln[glycated rhuMAb A] vs. time is a linear plot,
indicating the loss of glycation is a first order reaction.
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Dalton

Figure 3-4: ESI-MS mass profile of glycated rhuMAb A after 4weeks at 40°C.
A: In light chain three molecular mass were observed: native unglycated light
chain is the main peak.
a) native light chain mass 23286 dalton/mol;
b) one glucose added light chain with mass 23448 dalton/mol;
c) two glucoses added light chain with mass 23610 dalton/mol.
B: In heavy chain, two molecular mass were observed: native unglycated heavy is
the main peak.
a) native heavy chain mass 48791 dalton/mol;
b) one glucose added heavy chain with mass 48953 dalton/mol.
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Figure 3-5: Fluorescence intensity vs. time at 40°C.
In fluorescence spectroscopy, relative intensity at 350/440nm
increases over time at 40°C at 1 mg/ml rhMAb A concentration.
AGEs formation increased the fastest in first week, then plateaued
out.
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Peak 1, Peak 2

Figure 3-6: BAC fluorescence 350/440nm.
1) Fluorescence signal showed up in flow through portion of BAC.
2) There are two peaks, Peak 1 at 2.5 min overlapped with unglycated rhuMAb
A, Peak 2 at 2.7 min formed upon incubation.
Intensity of both peaks increases over time upon thermal stress at 40°C.
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Figure 3-7: BAC flow-through peak area vs. time at 40°C.
BAC signal of flow-through portion UV 280 nm for total protein
amount, fluorescence 350/440 nm for AGEs intensity.
Fluorescence signal showed an increase with time. Signal increased due
to formation of AGEs and the increase of total unglycated protein
amount.
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Figure 3-8: Comparison of BAC fluorescence signal and fluorescence
spectroscopy signal.
Two signal responses agreed with each other.
BAC –UV-Flu is suitable to monitor both glycation and advanced glycation
level on protein.
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Absorbance unit at UV 280nm

retention time ( min)

Figure 3-9: Overlaid chromatograms of tryptic peptide mapping of
glycated rhuMAb A before (blue trace) and after (red trace) thermal
stress at 40°C for 4weeks. (20min-50 min).
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Absorbance unit at UV 280nm

retention time ( min)
Figure 3-10: Overlaid chromatograms of tryptic peptide
mapping of glycated rhuMAb A before (blue trace) and after
(red trace) thermal stress at 40°C for 4weeks (50min-85min).
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Figure 3-11: Illustration of the total AGEs ELISA assay.
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Figure 3-12: Graphic comparison of total AGEs increase
upon thermal stress:
Brown color triangle trace is T0;
Blue color circle trace is one week;
Red color square trace is two weeks;
Green color circle trace is four weeks.
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Figure 3-13: Comparison on degradation rates of glycated rhuMAb A.
1) AGEs formation represented by fluorescence relative intensity
350/440nm jumped in first week then plateaued out.
2) Loss of affinity to BAC continued over four weeks.
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Figure 3-14: Potential detected AGEs structures.
Reference: Sell, D. R., Nagaraj, R. H., Grandhee, S. K., Odetti, P.,
Lapolla, A., Fogarty, J. and Monnier, V. M. (1991), Pentosidine: A
molecular marker for the cumulative damage to proteins in diabetes,
aging, and uremia. Diabetes /Metabolism Reviews 7: 239–251.
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Table 3-1: Summary of degradation products detected by peptide
map.
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Abstract
A forced glycation model on rhuMAb A and boronate affinity
chromatography technology were applied to evaluate the effect of drug product
compositions on the degradation of glycation adduct. Three formulation
composition factors were studied, such as pH, buffer, and oxidation control.
The results demonstrate that the pH is the key parameter to control degradation
pathways, as pH also determines the hydrolysis rate constant of glycated
rhuMAb A. The unique structure of rhuMAb A forms a rich electron donating
environment around K49. This unique environment determines the pH
dependence of glycation adduct’s hydrolysis rate. Buffer species and oxidation
levels do not impact the glycation adduct stability under the studied
pharmaceutical conditions. In addition, the effect of rhuMAb A’s glycation
level was also evaluated. The study demonstrated that higher protein glycation
levels slow down the overall hydrolysis rate of the glycation adduct,
presumably by providing a complex electron transferring system on protein.
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I. Introduction
In previous studies, it was shown that rhuMAb A can be used as a model to
study site-specific glycation and glycation adduct degradation pathways. In addition,
the boronate affinity chromatography (BAC) coupled with UV and fluorescence
detection is suitable to monitor both glycation level change and AGEs formation.
Previous protein characterization work and stability study demonstrated that the
glycation adducts of rhuMAb A degraded via two pathways, under thermal stress in a
typical pharmaceutical formulation at pH 6.5. The main reaction was hydrolysis to
reform unglycated rhuMAb A, while a minor reaction was the formation of AGEs.
To understand which parameters control the stability of glycation adducts
(Schiff base or Amadori product) during the final drug product storage, we used
glycated rhuMAb A as a MAb model and BAC as the analytical tool to investigate the
effect of four key parameters on glycation adduct stability, in a set of thermal stress
studies. These parameters included three important factors for formulation
compositions: pH conditions, buffer species, oxidative conditions. The final factor,
relevant to the protein, was the initial glycation level, which is based on rhuMAb A’s
( the active pharmaceutical ingredient) production process.
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II. Experimental
II. 1. Materials and Reagents
rhuMAb A lot I (22 mg/mL, PBS buffer, pH 7.4) and lot II (27 mg/mL, PBS
buffer, pH 7.4) bulk materials were produced using stable recombinant CHO cells
cultured using in-house using proprietary, serum-free media with and without
controlled glucose levels, respectively. D-Sorbitol (minimum 98%), R-D-glucose
(ACS reagent), iodoacetic acid (IAA; _99%), and R-cyano-4-hydroxycinnamic acid
(CHCA) were procured from Sigma-Aldrich (St. Louis MO). HPLC grade acetonitrile
(ACN) and methanol were purchased from Fisher Scientific (Fair Lawn, NJ). Water
used in all experiments was obtained from a Milli-Q Plus purification system
(Millipore, Bedford, MA).

II.2. Stability Study Setup and Parameters
pH conditions
Since both formation of Schiff bases and rearrangement of Amadori products
are pH depended, we investigated the overall effect of pH on the stability of glycated
rhuMAb A.

Six different pH conditions were tested between pH 4.5 and pH 7.0,

which is a typical pH range for protein therapeutics formulations. One drug product
lot, containing 36% glycated rhuMAb A, derived from common cell culture was used
in the pH study. The rhuMAb A drug product was buffer exchanged into six different
pH conditions, including 20mM sodium acetate buffer at pH 4.5 and 5.0, and 20mM
histidine/histidine hydrochloride buffer at pH 5.5, 6.0, 6.5, and 7.0. In all samples, the
final protein concentration was 0.5mg/ml with 8% trehalose, and 0.04% polysorbate
20.
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Buffer species:
Watkins, et al. had reported that phosphate ions could bind to the active site of
RNase and serve as a local catalyst for Amadori rearrangement of lysine residues near
the RNase’s active site. They established the buffer effect on the kinetics, and
specificity of glycaiton of RNase. (Watkins, N.G. et al. 1985 and 1987). To explore
the buffer effect on glycated rhuMAb A, we tested its stability in three buffers:
•

phosphate, to test the effect of phosphate ions on stabilizing glycated rhuMAb
A;

•

arginine, to test its inhibition effect on AGEs formation;

•

histidine as a typical formulation control.

In this study, 99% glycated rhuMAb A was buffer exchanged into three different
buffers: 20mM histidine hydrochloride, 20mM arginine phosphate and 20mM sodium
phosphate at pH 6.5. Final samples contained 20 mg/ml with 8% trehalose and 0.04%
PS20.

Control on Oxidative Conditions
Oxidation involved pathways are the keys for initiating AGEs formation. In
this study, one drug product lot with 15% glycated rhuMAb A was placed three
different oxidation conditions:
•

regular drug product vial with air in the head space;

•

drug product vial with N2 in the head space;

•

drug product vials with phenol added as an oxidation scavenger.
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The overall composition of this drug product lot is of 150mg/ml rhuMAb A in 200mM
histidine buffer, pH5.8 with 0.02% polysorbate 20.

Glycation level:
As previously reported, cell culture conditions impacted the final glycation
level of rhuMAb A (Yuk, I.H. et al. 2011).

It is unknown if glycation adduct

hydrolysis under in vitro storage would vary with initial glycation levels, so we
compared hydrolysis of glycated rhuMAb A among three different initial glycation
levels: 13%, 42% and 99%. Final samples contained 20mg/ml protein in 20mM
histidine buffer at pH 6.5.

Stability set up:
After samples were prepared under each condition, samples were stressed
thermally at 40°C for four weeks. After stresses, samples were analyzed to evaluate
the stability of glycated rhuMAb A. All the collected time points were analyzed with
boronate

affinity

chromatography

with

UV

and

fluorescence

detection

(BAC/UV/FLuo) assay. Total glycation level and AGEs formation were monitored by
boronate affinity chromatography.
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II.3. Boronate Affinity Chromatography (BAC)
High performance liquid chromatography (HPLC) with solvent delivery
system were used, where the analyte separation were performed with an Agilent 1100
series HPLC equipped with a thermostatic auto-sampler.
Early stage glycation adducts often can be identified by a BAC method using
A TSK gel boronate 5PW column 7.5x75mm. The mobile phase A was 50mM EPPS,
10mM Tris, 200mM NaCl, at pH 8.7, and mobile phase B was 500mM sorbitol in
mobile phase A. The mobile phase flow rate 1 mL/min and the column temperature
will be maintained at 40°C with UV detector at 280 nm and fluorescence detector at
350/440nm. The gradient for HPLC elution had been optimized for this rhuMAb A.
Due to the difficulty for quantification of fluorescence signal, the exact amount of
fluorescent AGEs cannot be determined, only relative fluorescence intensity is used to
compare different stability conditions.

II. 4 Enzymatic Digestion of rhuMAb A
Several enzymatic treatments were performed on rhuMAb A samples before
they were analyzed for reverse phase-HPLC, or mass spectrometric analyses, to
determine the amino acid sequence and structural integrity of rhuMAb A.
PNGase F Treatment. PNGase F was used to remove the oligosaccharides in
the Fc portion of a MAb. The rhuMAb A samples were buffer exchanged into 50
mM Tris buffer, pH 7.5, using a NAP-5 column. The protein concentration was
adjusted to 2.5 mg/mL. PNGase F was added in an enzyme-to-substrate ratio of
1:600 (w/w). The digestion was performed at 37°C overnight (15 h).
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Tryptic Digestion. Prior to tryptic digestion, rhuMAb was reduced with DTT
and then alkylated with IAA. Typically, 250 µL of antibody sample (2 mg/mL) was
mixed with 20 µL of 1 M DTT in 730 µL of 6 M guanidine, 50 mM Tris, pH 8.0.
The mixture was incubated at 37 °C for 1 h. It was then cooled to room temperature,
and 50 uL of 1 M (IAA) in 1 M NaOH was added for carboxymethylation. The
alkylation reaction was incubated at room temperature in the dark for 15-20 min. The
residual IAA was quenched by the addition of 10 µL of 1 M DTT. The reduced and
carboxymethylated rhuMAb A was then buffer exchanged into the digestion buffer,
which contained 25 mM Tris, 1 mM CaCl2, pH 8.3, using a PD-10 column
(Sephadex G-25 medium, GE Healthcare). Trypsin was added at an enzyme-tosubstrate ratio of 1:50 (w/w). The solution was mixed briefly and incubated in a
37°C water bath for 5 h. The digestion was terminated by adding 0.3% (v/v)
trifluoroacetic acid (TFA) to the solution. The digest was then stored at -70°C until
analysis.

II.5. Tryptic Peptide Mapping
Peptides profiles of tryptic-digested rhuMAb A were analyzed subsequently
by an RP-HPLC using a Jupitor C18 2.0x250 mm column at 45°C and UV detection
at 214nm. The flow rate was at 0.25ml/min, in mobile phase A: 0.1% TFA in water
and B: 0.09% TFA in acetonitrile. The gradient was optimized for this rhuMAb A.
By comparing the peptide maps of time zero and stressed glycated rhuMAb A, the
distinctive peptide factions on degraded glycated rhuMAb A were collected for
further characterization by MALDI-TOF MS/MS sequencing.
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II.6. Protein Chip Matrix Assisted Laser Desorption Ionization- Time-Of-Flight
mass spectrometry (MALDI-TOF)
Isolated tryptic peptides were spotted individually on a SCOUT 384 multiprobe plate with a CHCA matrix and analyzed in the positive mode using a Bruker
Ultraflex-I MALDI-TOF-TOF mass spectrometer (Bremen/Leipzig, Germany).
Sele8cted precursor ions were subjected to collision-induced dissociation with argon
as the collision gas. LIFT mode was used to analyze all fragment ions in single
sweep, and data were processed with Flex Analysis software.
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III. Results and Discussion
pH conditions:
BAC-UV 280nm to measure total glycation level change
The pH study revealed that glycation adduct stability is greatly dependent on
pH conditions. By comparing affinity chromatograms of the final time point (40°C
4weeks) at different pH conditions, we found that as pH increased, the rhuMAb A
samples lost the affinity to boronate ligand upon thermal stress (Figure 4-1), indicating
loss of glycation adduct. The total remaining glycation level is summarized in Table 41. It shows that samples stored at pH 4.5 had the highest remaining glycation level,
32.0% compared to 36% at time zero. From pH 5.5 to 6.0, remaining glycation level
dropped from 22.0% to 8.7%, while pH 7.0 had the lowest remaining glycation level,
only 5.6%.
The graph of glycation level vs. pH, confirms that the remaining glycation
level is inversely dependent on pH values (Figure 4-2). More importantly, the graph
shows a non-linear relationship between pH and remaining glycation level. There were
three pH responding sections, in which the glycation adduct’s stability responded to
pH change differently.

From pH 4.5 to 5.5, the glycation adduct level change

remained fairly mild. After thermal stress, the remaining glycation level differed about
5% per 0.5 pH unit, which is a modest response to pH change. From pH 5.5 to pH 6.0,
this region showed the most drastic relation ship between on the remaining glycation
level and pH. In this narrow pH range, with only 0.5 pH unit increases, the remaining
glycation level dropped 13.3%.

From pH 6.0 to 7.0, the final glycation level

decreased rapidly. In this range, the remaining glycation level was less than 8.7 %.
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However, the difference of remaining glycation level between pH 6.0 and pH 7.0 is
small, only approximately 2% per 0.5 pH unit. Therefore pH 5.5 to pH 6.0 is the most
sensitive pH range for glycated rhuMAb stability.

BAC-Fluorescence 350/440nm to measure AGEs formation
In contrast to loss of glycation adducts, fluorescence traces on BAC showed
two peaks with fluorescence signals at 350/440nm, which represent formation of
AGEs. Peak 1, at retention time 2.4 min, overlapped with unglycated adducts. Peak 2,
at retention time 3.6 min, is a new peak formed upon thermal stress. (Figure 4-3)
Comparing the fluorescence signals of different pH conditions after thermal
stress, we found that the intensity of fluorescence signal increased with increasing pH
(Figure 4-4). It is notable that, at pH 4.5, 5.0, 5.5 and 6.0, only peak 1, the unglycated
peak was observed. At pH 6.5 and pH 7.0, both peak 1 and peak 2 were observed.
This characterization result indicates that a new pentosidine-like AGEs-protein species
was formed upon thermal stress at higher pH conditions. However, even at pH 6.5 and
7.0, the majority of fluorescence signal intensity was attributed to peak 1, the
unglycated rhuMAb A.

AGEs formation demonstrated by peak 2, represented a

relatively small portion of total fluorescence intensity.
Comparing the pH dependence of total glycation level (Figure 4-2) and pH
dependence of AGE formations (Figure 4- 4), it is notable that below pH 6.5, the most
pronounced fluorescent peak was the hydrolysis product, unglycated rhuMAb A. This
indicates that at low pH range, pH 4.5 to pH 6.0, the hydrolysis of glycation adducts
was the main degradation pathway. At higher pH range, pH 6.5 to 7.0, both peak 1 and
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peak 2 were formed, but the intensity of peak 2 was small compared to peak 1. This
observation reveals AGE formation plays a minor role in the degradation pathway for
rhuMAb A. Overall, the preferred degradation pathways of glycation adducts were
driven by the pH conditions.

Determination of the hydrolysis rate constant
We can calculate the rate constant of hydrolysis at different pH conditions
based on the following two assumptions: the hydrolysis reaction rate was is much
greater than AGEs formation rate at all pH conditions; and the hydrolysis reaction was
a first order reaction, as we learned in Chapter 3.
The rate constant k can be derived from this function
k=ln([A0]/[An])/tn.
Where, k is the reaction’s rate constant and n is the particular time point, e.g. four
weeks etc. [A] is the concentration of reactant, [A0] is the initial concentration, [An] is
the final concentration. In our study, [A] represents the concentration of glycation
adducts measured by BAC.
The half-life of glycation adducts at each condition can be calculated as:
t 1/2= ln2/ak
Where, t

1/2

is the half-life of glycated rhMAb A. It means at this time point, the

concentration of glycation adducts equals to half of the initial concentration of
glycation adduct. The parameter a is the molar ratio of reactant for glycation adduct.
In our study, a =1. Table 4-1 summarizes the hydrolysis rate constant at different pH
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values. It demonstrates that the lower the pH, the slower glycation adduct hydrolysis.
Therefore, pH conditions determine the rate of hydrolysis of glycation adducts.
BAC can measure the amount of both Schiff base (aldimine) and Amadori
product (ketoamine). The total glycation level is the sum of these two species in which
cis-hydroxyal groups are still attached to rhuMAb A molecules.
Historically, Schiff base is known to be thermally unstable, and to undergo
reverse reaction easily in aqueous solution. Several studies have reported the
mechanism of Schiff bases hydrolysis (Figure 4-5). Jenck, et al. reported formation
and hydrolysis of the Schiff base intermediates such as transitional oxime and semicarbozone (Jenck, W.P., et al. 1963). Their study demonstrated a transition of the rate
limiting step. As pH conditions decreased, rate-determine step changed from Schiff
base formation/ hydrolysis under neutral to alkaline pH (step 1), to rate-determine
amine attack / decomposition of carbinol-amine under acidic pH (step 2). They also
found that the rate of hydrolysis markedly decreased in strong acid, which agrees with
the results in our study. Furthermore, Jencks’s group showed that under more acidic
conditions, a large fraction of Schiff base exists as the conjugate acid. The hydrolysis
rates decrease with decreasing pH for Schiff bases indicating an electron-donating
functional group on the molecule. The changes in rate with pH are correlated with the
conversion of Schiff bases to their conjugate acids.
We can determine the pKa of glycation adduct of rhuMAb A by plotting %
glycated rhuMAb A vs. pH, or kobs hydrolysis vs. pH ( Figure 4-6). The plateau area at
pH 5.75 represents the maximum glycation level change upon pH changes. pH 5.75 is
the pKa value of glycation adduct in Schiff base /conjugate acid form (Figure 4-6).
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The other aspect of glycation adduct stability is the Amadori rearrangement.
After dehydration, the Amadori rearrangement is favored at alkaline conditions
(Figure 4-7) at pH >7.0. The Amadori product is considered more stable than the
Schiff base. However, there are studies (Acharya, A.S. and, et. al., 1984, 1991) that
have shown the ketoamine linkage between glucose and protein to be reversible. In
our particular study subject of glycated rhMAb A, the major change in glycation was
observed on K49, the preferred glycation site. The observed rate of hydrolysis
decreased with decreasing pH. This pH-dependent hydrolysis indicates the electron
donor-enriched environment around lysine K49. The catalyst effect of three aspartic
acid residues surrounding K49 facilitates the formation of the Amadori product
(ketoamine) on K49. They also promotes K49 Amadori product reverse to Schiff base
(aldimine), then Schiff base reverse to unglycated rhuMAb A.
Therefore, between pH 4.5 and 5.5, the attack from nitrogen on the lysine
amine group to the carbon on carbonyl group of glucose is the rate-limiting step, while
adding a water to Schiff base to form conjugate acid is favored. The BAC was able to
detect both Schiff base and its conjugate acid. Since the conjugate acid is stable in
lower pH conditions (pH <5.5), overall glycation level of rhuMAb A is maintained. At
slightly higher pH, pH 5.5 to 6.0, around the pKa of the conjugate acid of Schiff base
(pH 5.75), the amounts of base and conjugate acid were equal. A big change of Schiff
base is needed to shift the pH of Schiff base/ conjugated acid system. Thus, we
observed at pH 5.5 to pH 6.0, there was a significant difference on the remaining
glycation level. BAC detected glycation adducts were mainly in Schiff base form. In
addition to rapid loss of glycation adducts, at pH 6.0 to 7.0, Amadori rearrangement
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occurred leading to a minor advanced glycation reaction. The BAC detected glycation
adducts are both Schiff base and Amadori products. Hence, the overall main reaction
in the studied pH conditions, from pH 4.5 to pH 7.0, is the reverse of glycation adduct
by Schiff base hydrolysis.
We can conclude that pH condition controls both the direction and rate of
Schiff base hydrolysis. Below the pKa of the Schiff base, glycation adducts are
relatively stable. However, at the pKa and above, Schiff base hydrolysis becomes the
preferred reaction, with Amadori rearrangement as a secondary reaction, leading to
loss of glycation adducts and an increase in prevalence of AGEs.

Buffer species
After 4 weeks of thermal stress at 40°C, no difference on BAC was found
among three buffer systems: histidine, arginine and phosphate buffers. Using the
same approach as described in the previous section, we calculated the degradation rate
constant in three buffers. The result demonstrated similar rate constants among
histidine, arginine, and phosphate buffer systems, with 0.10 week-1, 0.11 week-1, and
0.13 week-1, respectively. This observation indicates that these buffers did not cause
any difference on the reversibility of glycation adducts (Figure 4-8, Table 4-3). In
addition, the trends of AGE formation in three buffers detected by BAC were parallel
at fluorescence 350nm/440nm (Figure 4-9). Peptide mapping results confirmed that
even at the amino acid level, the degradation products are similar in three buffers
(Figure 4-10). Glycated rhuMAb A was shown to degrade to wild type rhuMAb A
(>80%) while a small portion (<10%) degraded to carboxyl-methyl-lysine (CML)
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(Figure 4-10), The relative proportion of these two degradation products were at
similar levels in all three buffers after thermals stress at 40ºC for 4 weeks.
Watkins, et al. has reported the catalysis effect of phosphate buffer on the
kinetics, and specificity of glycation on RNase (Watkins, N.G. et al. 1985/1987). By
binding the RNase active site, phosphate ion was localized on RNase, creating a
negatively charged environment. This increase of electron density helped nearby
lysine residue to form Amadori product during glycation. However, based on the
structure and function of the studied rhuMAb A, there is no phosphate ion binding site
to keep phosphate ion localized on protein. From the characterization work from
previous study and published work by Zhang (Zhang, B. et al. 2008), K49 was still the
primary susceptible site in both phosphate and sodium bicarbonate buffers.

Presence

of phosphate ion did not catalyze the glycation on this rhuMAb A. From the presented
stability result in this study, phosphate buffer did not show any effect on glycated
adduct hydrolysis, either. Thus, we hypothesize that phosphate ions cannot serve as a
catalyst in the glycation reaction of this rhuMAb A or be involved in the glycation
adduct hydrolysis without the active site to ensure its localization on rhuMAb A.
Therefore, phosphate ions did not affect hydrolysis rate of glycated rhuMAb A.
On the AGE formation, arginine was thought to be able to slow down the
advanced glycation reaction, by competing with rhuMAb A’s own amine groups, to
react with any carbonyl group on glycated rhuMAb A. However, in the presented
study, arginine did not affect AGEs formation on glycated rhuMAb A. One possible
reason is that advanced glycation reactions were minor at the studied pH condition, pH
6.5.
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Oxidation Control:
The oxidation controlled study showed very similar hydrolysis rate constants
for all conditions. Nitrogen (N2) purged vials resulted in the slowest rate constant, at
0.2%/week; then regular air purged vials at 0.22%/week; followed by phenol, an
oxidation scavenger, contained vials at 0.23%/week (Figure 4-11 and Table 4-3).
This indicated the degradation of the glycated rhuMAb A did not slow down at pH 6.5
in absence of oxidative reagent.

Initial Glycation Level
Table 4-4 summarizes the rate constants for all three initial glycation levels.
The hydrolysis rate dropped from 0.46 to 0.39 week-1 for the glycated rhuMAb A
species at 13% to 42% respectively. When the

protein was 99% glycated, the

glycated adduct degradation rate decreased to only 0.10 week-1, with a half life of ~ 7
weeks (Figure 4-12, Table 4-4). From BAC fluorescence signal, the AGEs formation
was fastest at the high glycation level ( Figure 4-13).
Furthermore, analysis of size heterogeneity at different glycation levels was
done by size exclusion chromatography. The result demonstrated that at higher
glycation level, more protein aggregates were formed. It is a evidence that protein to
protein interaction was more pronounced at higher glycation levels ( Figure 4-14).
As previous study showed (Chapter 2), the heavily glycated rhuMAb is a
mixture with complex structural modifications. With higher total glycation level, not
only K49 was glycated to a higher level, but other lysine residues were also modified.
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Previous studies by Zhang, et al. had shown that rhuMAb A can be glycated to
different levels. Table 4-4 summarizes the total glycated levels at each sites detected,
13% one (one site K49 only); 42% (6 sites, K49 level primary) ; 99% (7 sites, K49
primary about 90% as in chapter 2) (Zhang, B. et al. 2008).
In the forced glycation model, lysine residues buried inside the protein were
modified without the strong catalysis effect provided by neighboring aspartic acids.
Moreover, these glycated lysines were hard to be hydrolyzed (Table 3-1 in Chapter 3).
These much stable glycation sites may lead to further AGEs formation, as well as
protein-protein interaction to provide a complex protein network. Thus, we
hypothesize that the complexity and heterogeneity of final glycation states contributes
to a slower overall hydrolysis rate. The presence of more enduringly glycated sites
may provide a complex electron –transfer network on rhuMAb A that allows electron
transferring within the molecule, stabilizing the Schiff base.
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IV. Conclusions
1) Among the studied formulation parameters, pH is a key parameter to control
glycation adduct degradation pathways, it also determines the hydrolysis rate
constant of glycated rhuMAb A.
2) The unique structure of rhuMAb A creates a rich electron donating
environment around K49, which determines its site specific glycation and
contributes to the pH dependence of hydrolysis rate.
3) Buffer species and oxidation levels do not affect the glycation adduct stability
under the studied conditions.
4) Initial protein glycation level does affect the overall hydrolysis rate of
glycation adduct on rhuMAb A. This may be related to protein-protein
interaction involving electron transferring system among different glycated
sites.
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Absorbance unit at 280nm

Peak 1 Peak2

Retention time (min)

Figure 4-1: Glycation level after 4 weeks at 40°C.
UV 280nm on boronate affinity chromatography for pH 4.5 to 7.0.
It showed glycation level was the lowest at pH 7.0
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Figures 4-2: pH vs. remaining glycation level.
The pH dependence on glycated rhuMAb stability at 40°C pH 5.5 – 6.0
showed to be the most sensitive pH range for glycation change.
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Intensity of fluorescence 350/440nm

Peak 1 Peak 2

Retention time (min)

Figure 4-3: AGEs formation after 4 weeks at 40°C.
Fluorescence 350/440nm on boronate affinity chromatography for pH 4.5
to 7.0. AGEs fluorescence was the highest at pH 7.0.
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Figure 4-4: Fluorescence peak area at 350/440nm vs. pH.
It indicates the pH6.5 and pH 7.0 had significant AGEs formation after 4
weeks at 40°C.
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Figure 4-5: Illustration of Schiff base formation and hydrolysis.
At neutral to alkaline conditions, step 1 is the rate limiting step
At acidc pH, step 2 is the rate limiting step.
From reference: E.H.Cordes, and W. P. Jenck 1963. The Mechanism of
Hydrolysis of Schiff Base Derived from Aliphatic Amines Journal of
American chemistry Society, 85 (18) 2843-2848
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Figure 4-6: The pH dependence of glycation adduct hydrolysis.
Hydrolysis rate decreased with low pH. The pKa of Schiff base
is around pH 5.75.
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Figure 4-7: Amadori rearrangement: the C=N shifts to C=O, is
favored at high pH.
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Figure 4-8: Glycation level drop in three buffers.
It fits into linear plot on ln[ glycated rhuMAb A] vs time,
indicating, first order reaction rate of rhuMAb A hydrolysis.
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Figure 4-9: Fluorescence peak area vs. time in three buffers at
40°C. Total peak area of fluorescence signal 350/440 nm for
pentosidine-like AGEs increased over time.
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Figure 4-10: Comparison of degradation product of glycated rhuMAb
A upon thermal stress in three buffers: 20mM histidine, 20mM arginine
phosphate, 20mM sodium phosphate at pH 6.5. This bar graph showed
there are no glycation adduct degradation difference in the three buffer
systems.
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Figure 4-11: Comparison of glycated rhuMAb A hydrolysis in three
oxidation controlled conditions. N2 purged vial showed a slightly
slower hydrolysis rate.

124

Figure 4-12: Decreased glycation level in three lots with different initial
glycation levels at pH 6.5.
The rate of hydrolysis fits a linear regression, indicating a first order
reaction. At higher glycation level, hydrolysis rate was slower.
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Figure 4- 13: AGEs formation of glycated rhuMAb A over 4 weeks at
40°C in three different initial glycation levels.
Higher glycation level showed faster AGEs formation.
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Figure 4-14: Comparison of aggregate levels at 40°C of glycated
rhuMAb A in three different initial glycation levels. Higher glycation
level had higher initial aggregation level.
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pH condition
4.5
5.0
5.5
6.0
6.5
7.0

rate constant
k (week-1) at
40°C
0.045
0.091
0.13
0.35
0.43
0.51

remaining
glycation
%
32.0
25.0
22.0
8.7
6.4
5.6

t1/2
(week)
15.4
7.6
5.3
2.0
1.6
1.4

Table 4-1: Summary of first order rate constant of glycated
rhuMAb degradation at 40°C in different pH conditions
(with initial glycation level 36%).
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Buffer species
Histidine
Arginine
Phosphate

initial
glycation
level
99.3%
99.3%
99.3%

rate constant
k (week-1) at
40°C
0.10
0.11
0.13

t1/2
(week)
6.9
6.3
5.3

Table 4-2: Summary of rate constant of glycated rhuMAb A
degradation at 40°C in three different buffers ( pH is
constant at pH 6.5).
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Drug product condition

rate constant
k (week-1)
at 40°C
0.22

half life
t1/2
(week)
3.2

Fill with N2 in the head space

0.20

3.5

Phenol added to DP

0.23

3.0

Fill with regular air in the head
space

Table 4-3: Summary of rate constant of glycated rhuMAb A
degradation at 40°C in three different oxidation conditions.
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Material
Lot a
Lot b
Force
glycated

initial
glycation
level

rate constant
k (week-1 )
at 40°C

t1/2
(week)

13%
42%

0.46
0.39

1.5
1.8

99%

0.10

6.9

number of
detected
glycation sites
1 site
6 sites
7 sites

Table 4-4: Summary of rate constant of glycated rhuMAb A
degradation at 40°C in three different initial glycation levels.All
samples were in 20mM histidine buffer pH 6.5.
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